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ABSTRACT  
MECHANISMS UNDERLYING THE SENSITIVITY AND RESISTANCE OF 
GASTRIC CANCER CELLS TO MET INHIBITORS 
Rebecca Lynette Schroeder, B.S. 
 
Advisory Professors: David McConkey, Ph.D. 
       David Hong, M.D. 
 
MET amplification has been clinically credentialed as a therapeutic target in gastric 
cancer, but the molecular mechanisms underlying sensitivity and resistance to MET 
inhibitors are still not well understood. Using whole-genome mRNA expression profiling, we 
identified autophagy as a top molecular pathway that was activated by the MET inhibitor 
crizotinib in drug-sensitive human gastric cancer cells, and functional studies confirmed that 
crizotinib increased autophagy levels in the drug sensitive cells in a concentration-
dependent manner. We then used chemical and molecular approaches to inhibit autophagy 
in order to define its role in cell death. The clinically available inhibitor of autophagy, 
chloroquine, or RNAi-mediated knockdown of two obligate components of the autophagy 
pathway (ATG5 and ATG7) blocked cell death induced by crizotinib or RNAi-mediated 
knockdown of MET, and mechanistic studies localized the effects of autophagy to 
cytochrome c release from the mitochondria. Overall, the data reveal a novel relationship 
between autophagy and apoptosis in gastric cancer cells exposed to MET inhibitors. The 
observations suggest that autophagy inhibitors should not be used to enhance the effects of 
MET inhibitors in gastric cancer patients. 
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1. Introduction 
1.1 Gastric Cancer 
 
The International Agency for Research on Cancer (IARC) and the World Health 
Organization (WHO) identify cancer as the second leading cause of death worldwide, 
contributing to 8.8 million deaths in 2015 (1). Cancers of the lung, liver, colon, stomach and 
breast are the most common disease sites contributing to this high mortality rate, with 
these five cancer types comprising more than half of the total cancer-related deaths for 
2015.  Of these disease sites, stomach cancer was credited with 800,000 deaths in 2015(1).   
Although our understanding of significant risk factors and screening methods for 
gastric cancer has improved over the last decade, it remains the fifth most prevalent cancer 
and third leading cause of cancer-related death worldwide (1-4). Stomach cancer cases 
occur at a higher incidence rate (71%) in less developed regions with more than half of all 
gastric cancer cases occurring in eastern Asia. This variable distribution correlates with the 
increase incidence of biologic and environmental risk factors occurring in these populations 
as opposed to regions with more developed populations (i.e. North America and Europe) 
which have experienced substantial declines in gastric cancer incidence since the 1970’s (5).  
Gastric cancer is a slowly occurring process with exposure to chemical carcinogens through 
alcohol and tobacco use, consumption of foods preserved by salting, family history, obesity, 
and exposure to the infectious agents bacterium Helicobacter pylori (H. pylori) and  
Epstein–Barr virus (EBV) being the primary etiological determinants [Figure 1.1] (6, 7).   
Gastric cancer incidence is twice as high in men as compared to women, and this is 
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attributed to the protective effect of female sex hormones, at least in tumors initiated by H. 
pylori infection.  In women, estrogen levels are sufficient to decrease oncogenic signaling 
and attenuate the chronic inflammatory response in reaction to the chronic inflammatory 
state caused by H. pylori infection (8). 
 
 
Figure 1.1 Risk factors associated with gastric cancer.  Genetic and environmental 
risk factors are associated with the development of gastric cancer and include a family 
history of certain inherited disease, infection with H. pylori, ethnicity, sex, and exposure to 
toxins through ingestion of certain foods and tobacco use (6). 
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Gastric cancers are overwhelming classified as adenocarcinomas, which can be 
further histologically classified based on Lauren classification as intestinal and diffuse (9, 
10).  The development of gastric cancer is a multifactorial/multistep process, and the 
majority of intestinal type gastric cancers are initiated by environmental factors and the 
majority of diffuse gastric cancers are derived from genetic factors (6, 9). Symptoms of 
gastric cancer in the early stages of the disease mimic other common gastric issues 
including epigastric pain, bloating and nausea.  Because of this most patients do not present 
with clinical signs specific to gastric cancer such as weight loss, jaundice, ascites, and 
hepatic enlargement until they have advanced disease with local or distant metastasis (6). 
The National Cancer Institute identifies the liver, lung, and peritoneum as the primary 
metastatic sites for gastric cancer.  Patients with early stage gastric cancer have a high 
overall survival rate, but unfortunately, only 20% of all cases are early stage.  The survival 
rate for advanced stage cases is much lower overall and is highly dependent on anatomical 
location and histological variant. Patients with localized distal disease have a 50% survival 
rate compared to a much lower survival rate of 10% for patients with localized proximal 
gastric cancer (11). 
The frontline treatment strategies for gastric cancer are surgical resection, 
chemotherapy and radiation therapy with mitomycin, fluorouracil, cisplatin, paclitaxel and 
docetaxel being the primary chemotherapeutic agents (6).  Although chemotherapy and 
radiation correlate with prolonged survival in early stage disease, most patients, 
unfortunately, present with advanced stage tumors were the only curative option currently 
available is surgical resection (12). Patients with nonresectable disease have few 
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therapeutic options and are primarily treated with chemotherapy regimens using 
combinations of the previously mention agents, were the median survival  is only 10 months 
[Table 1.1] (13).  Because of this lack of effective therapeutic options the need to identify 
alternative ways to treat gastric cancer of the utmost importance.   
 
Table 1.1 Advanced gastric cancer treatment regimens when chemoradiation is not 
recommended.  
*Reprinted with permission from NCCN Guidelines® & Clinical Resources (14) 
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1.2 Genomic alterations in gastric cancer 
 
One aspect of tumor biology that has emerged as an attractive therapeutic target in 
multiple cancer types is the alteration of a family of cell surface receptors, receptor tyrosine 
kinases (RTKs) (15). RTKs mediate important signaling pathways involved in the control of 
many essential processes including cell proliferation/growth, differentiation, migration, and 
survival through ligand-induced activation by binding various extracellular signaling 
molecules (i.e. growth factors, hormones, and cytokines) (12, 16). When alterations occur 
through mutation, amplification or chromosomal translocation these RTKs display aberrant 
and constitutive activation leading to increased proliferation, migration and survival (17).  
Deng, et. al. identified the most predominant molecular alterations in a panel of 233 
gastric cancers and RTK alterations were among the most frequent alterations occurring in a 
third of the samples (18). This group specifically identified the RTK MET as one of the top 
genomic alterations in their cohort of gastric cancers (18). Other groups have been able to 
correlate molecular targets (FGFR, PI3K, MET, HER2, VEGF, and EGFR) with anatomical 
location and histological classification (proximal non-diffuse, distal non-diffuse, and diffuse) 
in gastric cancer[Figure 1.2] (10).  Specifically, MET amplification was correlated with higher 
incidence in the proximal non-diffuse subtype. This correlation is serving as a valuable tool 
to aid in the selection of patient populations for targeted molecular therapies and the 
identification of more effective predictive biomarkers  (10). 
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Figure 1.2 Gastric cancer subtypes.   Correlation between molecular targets, 
anatomical location, and histological classification for each gastric cancer subtype (10). 
Subtypes of gastric cancer based on anatomical and histological classification, and 
important molecular targets implicated in each subtype. 
*Reprinted with permission of Therapeutic Advances in Gastroenterology. Hilda Wong, 
Thomas Yau, Molecular targeted therapies in advanced gastric cancer: does tumor histology 
matter? SAGE Publications 01/01/2013 (10). 
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1.3 MET in gastric cancer 
 
MET, also known as hepatocyte growth factor receptor (HGFR), is a transmembrane 
cell surface receptor expressed in epithelial cells of organs such as the liver, kidneys and 
bone marrow (19). MET is comprised of two subunits (glycosylated extracellular α-subunit 
and a transmembrane β-subunit) that are linked by a disulfide bridge (20). MET forms a 
heterodimer upon binding with its ligand hepatocyte growth factor (HGF) resulting in 
autophosphorylation of two tyrosine residues (Y1234 and Y1235) on the catalytic domain 
and phosphorylation of two tyrosine residues (Y1349 and Y1356) on the carboxy-terminal 
tail (21).  
Phosphorylation of the tyrosine residues allows for the engagement of various signal 
transducers and adaptor proteins that activate and signal through two main oncogenic 
signaling pathways: the mitogen-activated protein kinase (MAPK) cascade and the PI3K/Akt 
signaling axis as well as several other signal transduction pathways (STAT, NOTCH, and beta-
catenin)  (19, 22). Signaling through these pathways allows for the regulation of multiple 
biologic processes (i.e. cellular metabolism, cell cycle progression, 
migration/motility/invasion, autophagy, proliferation and cell survival/protection from 
apoptosis) that are essential for tissue homeostasis (Figure 1.3).  
Therefore, deregulation of MET signaling plays a crucial role in cancer development. 
To date, numerous different cancer types (lung, gastric, ovary, colon, breast, kidney, 
thyroid, and liver) have been associated with deregulation of MET signaling (23). MET 
signaling is modulated and deregulated through mutation, chromosomal translocation, 
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amplification or other mechanisms in these cancers. MET is of particular interest because 
multiple studies annotated the frequency of MET amplification in gastric cancers and 
reported rates of 9-30% (24-26), with high-level MET amplification in about 4% (12/287) of 
tumors (27).  Additionally, in multiple studies MET amplification was associated with poor 
patient outcomes (25, 28) (Figure 1.2).  
 
  
Figure 1.3 MET signaling pathways. Activated MET signals through multiple signaling 
cascades including the MAPK pathway (RAS/RAF/MEK/ERK) and the PI3K pathway 
(PI3K/AKT/MTOR) which in turn regulates multiple cellular processes highlighted in the 
figure (29, 30). 
 
*Reprinted with permission of Immunotargets and Therapy by Dove Medical Press Ltd. This 
work is published by Dove Medical Press Limited, and licensed under Creative Commons 
Attribution: Non-Commercial (unported, v3.0) License (30). 
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Specifically, two studies have highlighted this correlation between MET amplification 
and poor survival outcomes in gastric cancer. The first study analyzed tissue from 472 
gastric cancer patients who had undergone curative surgery and had DNA samples available 
for qPCR analysis (28). They found that 21.2% of the samples had amplified MET  (>4.0 
copies), and these patients experienced poorer overall survival as compared to the patients 
without MET amplification(28) (Figure 1.4 top panel) (28).  The second study used silver in-
situ hybridization (SISH) to identify MET gene amplification in tissue collected from a panel 
of 381 gastric cancer patients (25). They found that 3.4% of the tumors analyzed had MET 
gene amplification, and overall survival and disease-free survival decreased with increasing 
MET copy number (25) (Figure 1.4 bottom panel). Addtionally they correlated overall 
survival according to the level of MET protein expression measured by IHC and found that 
2.1% of the tumors had high levels (+3) of IHC staining  and these patients had shorter 
survival time compared to the other groups (0, +1, +2). 
This correlation between MET gene amplification and high grade MET protein 
expression link to poor outcome, coupled with the fact that MET has been credentialed as a 
viable RTK target made MET inhibitors attractive as tools for therapeutic intervention. 
Multiple preclinical studies indicate that MET amplification creates MET dependency in 
gastric cancer cells [27, 28] and recent clinical trials demonstrated that MET inhibitors had 
significant clinical activity (25, 26); particularly in patients whose tumors contained MET 
amplification (31-33).   
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Figure 1.4 Overall survival based on MET amplification  status. Top panel: MET 
status (amplification or protein expression) was correlated with survival data in a panel of 
452 patients. (A) MET amplification (+) vs. (-). (B) MET amplification with c-Met protein 
activation (+) vs (-) status. MET amplification was determined using qPCR analysis and MET 
protein expression was determined using IHC staining against MET (total) and phospho-Met 
(pY1349) (28). Bottom panel: Overall survival (Kaplan–Meier curves) based on MET gene 
copy number and IHC MET activation for a panel of 438 patients.(A) IHC MET activation 
grade 0,1,2, or 3. (B)  Gene amplification (GA) vs. high polysomy (HP) vs. wild-type MET 
(Negative) (25).    
 
*Top Panel: Reprinted with permission of Oncology Reports.  Impact of MET amplification 
on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic 
target. Lee J1, et al. Oncol Rep. 2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 
2011 Mar 18 (28). 
 
*Bottom Panel: Reprinted from British Journal of Cancer, (107), H E Lee, M A Kim, H S Lee, E-
J Jung, H-K Yang et al., MET in gastric carcinomas: comparison between protein expression 
and gene copy number and impact on clinical outcome, 325–333, Copyright (2012), with 
permission from Nature Publishing Group.(25) 
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1.4 MET-targeted therapy in gastric cancer 
 
Currently there are numerous therapeutic strategies aimed at targeting MET 
including 1) ATP-competitive MET and TKI inhibitors: foretinib (GSK1363089), crizotinib (PF-
2341066), cabozantinib (XL184), S49076, MK-2461 and AMG 337; 2) allosteric tyrosine-
kinase inhibitors (TKIs): tivantinib (ARQ197); and 3) anti-MET and anti-HGF monoclonal 
antibodies (mAbs): onartuzumab (MetMAb™),  rilotumumab (AMG-102), ficlatuzumab (AV-
299), TAK-701, emibetuzumab (LY-2875358), ARGX-111 and EM1-mAb  (30, 34-37) [Figure 
1.5 and Table 1.2](34, 38).  These therapeutic strategies have an advantage over traditional 
chemotherapy and radiation as they have targeted mechanisms to induce cell death in 
tumor cells specifically and do not kill cells indiscriminately as is the case with traditional 
methods(39). ATP-competitive small molecule tyrosine inhibitors compete with the ATP 
binding site of the catalytic domain of tyrosine kinases and induce a cytotoxic response by 
inhibiting the sustained oncogenic signaling driven by the aberrant activation of the RTK 
(40). Monoclonal antibodies induce a cytotoxic response resulting in apoptosis by various 
antibody-directed mechanisms including the blockade of ligand-receptor growth or survival 
pathways, antigen crosslinking and activation of death receptors (41). The mechanism of 
action of each of these various classes of therapeutics ultimately leads to the induction of 
growth arrest and programmed cell death, apoptosis (39-41).  
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Table 1.2 Therapeutic strategies aimed at targeting MET. 
* Reprinted with permission Creative Commons CC-BY-NC 3.0 license(38). 
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Figure 1.5 Therapeutic inhibitors targeting MET. Novel therapeutic strategies to 
target MET included: ATP-competitive inhibitors, tyrosine kinase inhibitors (TKIs), and anti-
MET and anti-HGF monoclonal antibodies (mAbs) (34). 
 
*Reprinted with permission of Nature Publishing Group. Conor A. Bradley, Manuel Salto-
Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero Targeting c-
MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews 
Clinical Oncology 4.4.2017 (34). 
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1.5 Apoptosis 
 
Although MET-targeted RTK inhibitors have clinical activity, not all MET-amplified 
tumors respond, and a deeper understanding of the molecular determinants of response 
and resistance is therefore crucial. MET inhibitors have both cytotoxic and cytostatic effects 
in MET-amplified cells, and two studies have highlighted the preclinical correlation between 
MET amplification and extreme sensitivity to MET inhibition in gastric cancer cells (42, 43). 
While profiling multiple cancer types for sensitive to two TKIs:  PHA-665752 (MET tyrosine 
kinase inhibitor) and gefitinib (EGFR tyrosine kinase inhibitor), the Haber Lab identified a 
correlation between MET amplification and extreme sensitivity, via decreased cell 
proliferation and growth rates, to the MET inhibitor crizotinib (42). Okamoto and associates 
further investigated this finding by looking deeper into the anti-tumor mechanisms 
associated with MET inhibition in MET-amplified gastric cancers (43). They found that MET-
amplified gastric cancer cells undergo growth arrest and apoptosis when MET is inhibited 
via chemical (crizotinib) and genetic (RNA interference) depletion methods. Also, MET 
depletion caused significant decreases in MET downstream signaling resulting in decreased 
ATK and ERK phosphorylation (43). Additional, mechanistic studies implicated upregulation 
of the pro-apoptotic BCL2 family protein BIM and downregulation of several pro-survival 
genes, including the IAP family members c-IAP1, XIAP, and survivin, in crizotinib induced cell 
death (43). This suggests that BIM upregulation may contribute to the pro-apoptotic effects 
of crizotinib in MET-amplified gastric cancer cells, but further investigation is needed to 
identify the relative contributions of apoptosis and growth arrest in regards to the anti-
tumor effects of MET inhibition.  
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Apoptosis is the process of programmed cell death commonly characterized by cell 
shrinkage, membrane blebbing, nuclear condensation, and DNA fragmentation [Figure 1.6] 
(44, 45). This process occurs via initiation through two distinct energy-dependent 
mechanisms, the intrinsic and extrinsic apoptotic pathways (44). Extrinsic apoptosis is 
death-receptor initiated, and intrinsic apoptosis is controlled by the mitochondria, but both 
pathways converge on the same execution pathway which is initiated by caspase 3 cleavage 
(44). Caspases are a family of proteolytic enzymes that help carry out the apoptotic cascade 
and are characterized into three main subcategories: initiator caspases (caspase 2, caspase 
8, caspase 9, caspase 10), executioner caspases (caspase 3, caspase 6, and caspase 7), and 
inflammatory caspases (caspase 1,caspase 4 and caspase 5) (46). During times of cellular 
stress, the intrinsic pathway is activated by release of cytochrome c from the mitochondria 
into the cytosol resulting in the formation of the apoptosome from the activation and 
binding of cytochrome c, APAF-1 and caspase 9(47). Apoptosome formation allows for the 
activation of executioner caspases and the degradation of cellular components that are 
subsequently phagocytosed by macrophages or adjacent normal cells and produce the 
hallmark characteristics associated with apoptosis, previously mentioned.  Various anti-
apoptotic proteins negatively control the two apoptosis pathways. Specifically for the 
extrinsic pathway activation of caspase 8 and caspase 3 are inhibited by c-FLIP and XIAP and 
regulation of the intrinsic pathway is controlled by the balance of proapoptotic (i.e. Bax, 
Bak, and  Bid) and anti-apoptotic (i.e. Bcl-2, Bcl-xL, Mcl-1, and XIAP) proteins (48). Apoptosis 
is distinct from other forms of cell death such as necrosis [39]. Necrosis is primarily 
triggered by external factors such as infection or trauma and does not require energy and 
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elicits an immune response from the release of its cellular components to neighboring cells 
through the loss of membrane integrity [35]. The understanding these distinct processes is 
important for characterization of molecular response to cancer therapeutics. 
 
Figure 1.6 Extrinsic and intrinsic apoptotic pathways. Apoptosis is initiated through 
two distinct mechanisms. 1).Receptor-mediated induction, extrinsic signaling pathway, 
involves ligand-dependent activation of death receptors (Fas, TNFαR, DR3, DR4, and DR5) 
followed by activation of caspase 8 and caspase 3 resulting in apoptosis. 2) Mitochondria-
mediated induction, intrinsic signaling pathway, is triggered by cellular stress (i.e. DNA 
damage, ER/metabolic stress, and hypoxia) and requires activation of BAX/BAK to initiate 
mitochondrial outer membrane permeabilization and cytochrome c release. The 
apoptosome is then formed, composed of caspase 9 and caspase 3, resulting in apoptosis.  
 
*Reprinted from Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis, (768), Rima Beesoo, Vidushi Neergheen-Bhujun, Ranjeet Bhagooli, Theeshan 
Bahorun, Apoptosis inducing lead compounds isolated from marine organisms of potential 
relevance in cancer treatment, 84-97, Copyright (2014), with permission from Elsevier.(48) 
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1.6 Autophagy 
 
 In addition to apoptosis, macroautophagy (autophagy) is a well characterized 
process that has been implicated in the response as well as resistance to MET targeted 
therapies (49). Autophagy is an intracellular process that is involved in the degradation and 
recycling of damaged and dysfunctional cellular components via a lysosomal degradation 
pathway  (50). The process of autophagy is important for the maintenance of overall cellular 
health by inhibiting the buildup of toxic cellular waste over time through the clearance of 
damaged proteins and organelles (51). The clearance and recycling of damaged cellular 
components allows for the preservation of cell viability during times of cellular stress that 
would otherwise lead to the activation of the apoptotic cascade (52). Autophagy is activated 
by cellular stress created through oxidative stress, protein aggregation and nutrient 
deprivation and is commonly associated with processes including differentiation, infection, 
and cancer (53). 
The primary molecular signaling pathway associated with autophagy is the 
phosphoinositide 3-kinase (PI3K) pathway (53) [Figure 1.7]. This pathway is involved in 
regulating a multitude of cellular functions including metabolism, growth, proliferation, 
survival, transcription and protein synthesis. The PI3K pathway signals through protein 
kinase B (AKT) and the kinase mammalian target of rapamycin (mTOR), which is the primary 
regulator of autophagy within the cell (54). mTOR is comprised of two complexes, MTORC1 
and MTORC2, that both play independent roles in the regulation of autophagy (55).  As a 
result of this dynamic regulation, autophagy is controlled through the modulation of mTOR 
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to the extent of that when mTOR is activated through the AKT signaling autophagy is 
suppressed and when mTOR is inhibited through AMP-activated protein kinase (AMPK) 
activation autophagy is induced (53, 56, 57).  Nutrient deprivation or cellular stress initiates 
a downstream cascade through multiple molecules, including MTOR inhibition, that 
ultimately leads to autophagosome formation. The autophagosome is a double-membrane 
vesicle that forms in a multi-step process and allows the process of autophagy 
(sequestration, transport to lysosomes, degradation, and utilization of degradation 
products) to occur [Figure 1.7] (58).  The molecules involved in autophagosome formation 
are several kinases (serine/threonine) ULK1, ULK2, and UKL3 (UNC-51-like kinase -1, -2, and 
-3); the autophagy-related (Atg) genes ATG5, ATG7,ATG12, ATG10, and ATG16; and the 
microtubule-associated protein 1A/1B-light chain 3 (LC3) (59).   Autophagy is often referred 
to as the double-edged sword of cancer modulation because it can act both as a tumor 
suppression mechanism and tumor cell survival mechanism (60). Autophagy is found to be 
both up-regulated and down-regulated in cancer and is highly dependent on cellular 
context as to which state is present within any given cell (61).  Interestingly, there is 
evidence that indicates that there is significant overlap (crosstalk) between autophagy and 
apoptosis and that the two biologic processes are connected in both positive and negative 
manners (62). This dynamic relationship between autophagy and apoptosis functions in 
many capacities and is primarily determined by the state of the cell. Autophagy generally 
blocks apoptosis induction during times of cellular stress (acting as a survival mechanism) 
and apoptosis-initiated caspases block autophagy induction when the cells has reached a 
level of damage that is irreversible (acting as a cell death mechanism) (62). Also, in extreme 
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cases, autophagy can even act as an alternative cell death mechanism (63). Because of the 
diversity of activation mechanisms and biologic roles that autophagy plays within cells it has 
the distinct ability to both promote and inhibit tumorigenesis (50). This makes autophagy an 
attractive target for molecular therapies and further investigation into its role within 
specific subsets of cancer cells is a top priority for researchers. 
 
Figure 1.7 Autophagy.  The molecular determinates of autophagy that control the highly 
conserved multi-step “self-digestive” process. These steps include vesicle nucleation, 
vesicle elongation, autophagosome fusion with the lysosome, and proteolytic degradation 
of engulfed molecules (61, 64). 
 
*Reproduced with permission of Clinical Cancer Research by American Association for 
Cancer Research and HighWire Pres. Molecular Pathways: Autophagy in Cancer—A Matter 
of Timing and Context. Michelle Cicchini, Vassiliki Karantza and Bing Xia. Clin Cancer Res 
February 1 2015 (21) (3) 498-504.(61) 
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1.7 Summary and scope of dissertation 
 
 In this dissertation, I sought to better understand the molecular determinants of 
sensitivity and resistance to MET inhibition in human gastric cancer. Here I present the 
findings of one comprehensive study that is divided into two main parts pertaining to MET 
inhibitor sensitivity and subsequently the role of autophagy induction in response to MET 
inhibition in MET-amplified gastric cancer. First, in Chapters 3 and 4, I examined the effects 
of MET inhibition on gastric cancer cells as it pertains to cell death, growth arrest and global 
gene expression modulation. Using the data obtained from these experiments I identified 
two gastric cancer cell lines with extreme sensitivity to MET inhibition via incubation with a 
tyrosine kinase inhibitor, crizotinib.  Both of the sensitive gastric cancer cell lines have 
amplified MET. Once I examined and identified the molecular determinants of sensitivity to 
MET inhibition, I sought to identify additional synergistic targets and potential resistance 
mechanisms. In Chapter 5, I evaluated the effects of crizotinib on gastric cancer cells with 
MET amplification and identified autophagy as a top biologic process modulated by MET 
inhibition. Then I sought to delve deeper into the understating of how autophagy 
modulation is interacting with MET inhibition in gastric cancer cells. Because autophagy has 
been shown to be both tumor suppressive and tumor promoting depending on cellular 
context, there is a need for a better understanding of how autophagy modulation influences 
response to MET inhibition and this dissertation seeks to contribute to this aim. 
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Chapter 2. MATERIALS AND 
METHODS 
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2.1 Materials and Methods for Chapter 3 
 
2.1.1 Cell lines and culture:  MKN45, MKN74, NUGC-3, NUGC-4, and IM95 gastric cancer 
cells were a gift from Julie G. Izzo, M.D., Department of Experimental Therapeutics, MD 
Anderson. KATOIII, NCI-N87, SNU-16, SNU-5, AGS, Hs746t, and SNU-1 gastric cancer cells 
were obtained from American Type Culture Collection (Manassas, VA). HGC-27 gastric 
cancer cells were obtained from Sigma-Aldrich (St. Louis, MO). All cells were validated by 
DNA fingerprinting using AmpFlSTR® Identifiler® Amplification kit (Applied Biosystems, 
Foster City, CA), performed by the MD Anderson Characterized Cell Line Core. All gastric 
cancer cells (except for SNU-5) were maintained in RPMI-1640 medium supplemented with 
10% FBS (HyClone/Thermo Scientific, Waltham, MA), minimum essential medium (MEM) 
vitamins, sodium pyruvate (Mediatech/Corning Cellgro, Manassas, VA), L-glutamine, non-
essential amino acids, penicillin/streptomycin (Lonza, Switzerland), and HEPES buffer. SNU-
5 cells were cultured in Iscove's modified Dulbecco's medium supplemented with 10% FBS, 
MEM vitamins, L-glutamine, sodium pyruvate, non-essential amino acids, 
penicillin/streptomycin, and HEPES. All cells were grown at 37° C in 5% CO2.  
2.1.2 Chemicals and antibodies:  Crizotinib was purchased from Selleck Chemicals 
(Houston, TX). Bortezomib was purchased from ChemieTek (Indianapolis, IN).  Propidium 
iodide was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies were obtained from 
the following sources: MET, p-MET and cleaved PARP from Cell Signaling Technology 
(Beverly, MA); anti-mouse/ anti-rabbit HRP-labeled secondary antibodies from Promega 
(Madison, WI); and β-actin from Sigma-Aldrich (St. Louis, MO). 
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2.1.3. CCLE Methods: mRNA expression data was obtained using Affymetrix Human 
Genome U133 Plus 2.0 arrays according to the manufacturer’s instructions. Copy number 
variation data was obtained using genome-wide human Affymetrix SNP Array 6.0. 
Pharmacological characterization was automated and performed with an ultra-high 
throughput screening using 72 to 84 hours Cell Titer Glo Assays (Promega) (65).  
2.1.3 Cell proliferation assay: The panel of 13 gastric cancer cells was plated in quadruplet 
replicates in 96-well plates at a density of 5x103 cells per well. The cells were allowed to 
attach overnight before exposing them to the indicated concentrations of crizotinib (ranging 
from 0, .01-10uM) for 5 days. Conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to formazan salt was used to measure relative numbers of 
viable cells in each well (66). Following drug exposure, 50μL of MTT solution (50μg/ml in 
PBS) was added to each well and cells were incubated for 2 more hours. Next, the medium 
was aspirated and replaced with DMSO (100μL). A colorimetric assay using a standard 
micro-plate reader was used to determine the amount of MTT in each well via was 
quantified by measuring the optical densities (ODs). IC50 values were then correlated by 
using the raw absorbance values. 
2.1.4 Copy number assay: DNA was isolated from gastric cell lines (MKN45, MKN74, NUGC-
4, SNU-5 and Hs746t) using a genomic DNA extraction kit according to the manufacturer’s 
protocol (Qiagen). MET gene copy number was determined using commercially available 
and pre-designed TaqMan Copy Number Assays (Applied Biosystems, Foster City, CA) as 
described previously (67). The primer used for the MET gene was Hs05005660_cn. 
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(Location: Chr.7:116778578 on GRCh38, Cytoband: 7q31.2). The TERT locus was used for 
the internal reference copy number. Real-time genomic PCR was performed in a total 
volume of 20μL in each well, which contained 10μL of TaqMan genotyping master mix and 
20ng of genomic DNA and each primer. The PCR conditions were 95°C for 10 minutes, 40 
cycles of 95°C for 15 seconds, and 60°C for 1 minute. Data were analyzed using SDS2.2 
software and CopyCaller software (Applied Biosystems).  
2.1.5 Cell death assay (apoptosis): Cells were plated in 6-well plates and were allowed to 
attach overnight. Cells were then exposed to crizotinib (0, .001uM, .01uM, .1uM, 1uM) for 
48 hours and collected via trypsinization. Cell pellets were washed once in 2ml of cold PBS 
and resuspended in 0.5mL of PI-FACS buffer which contains: propidium iodide (PI) solution 
(100μg/mL), triton x-100, sodium citrate and PBS for 1-3 hours at 4° with limited exposure 
to light.  Apoptosis was quantified by propidium iodide staining coupled with flow cytometry 
by FACS (fluorescence activated cell sorting) analysis on the FL3 channel of a Beckman 
Coulter FC500 flow cytometer (68). The method involves propidium iodide staining of 
permeabilized cells; apoptotic cells release the DNA fragments produced as a consequence 
of the endogenous endonuclease activation that is associated with apoptosis, and they 
appear as hypodiploid cells when they are measured by flow cytometry.   
2.1.6 Immunoblotting: Phospho and total MET: cells were harvested by scrapping and lysed 
in buffer containing 50mM Tris-HCL, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 1% sodium 
deoxycholate, 0.01% SDS, 2mM sodium orthovanadate (Na3VO4), 1mM NaF, 1mM 
glycophosphate, 1mM PMSF and complete mini protease/ phosphatase inhibitor tablets 
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(Sigma-Aldrich). PARP: cells were harvested by scraping and lysed in buffer containing 0.5% 
(w/v) SDS and then the membrane was disrupted by sonication for 30 seconds before being 
stored on ice.   Protein concentrations were measured using the BCA Protein Assay Kit 
(Thermo Scientific, Rockford, IL). Lysates were boiled in sample buffer (62.5 mmol/L Tris-HCl 
(pH 6.8), 10% (w/v) glycerol, 100 mmol/L DTT, 2.3% SDS, 0.002% bromophenol blue) for 5 
minutes and cooled at room temperature for 10 minutes. Samples were then separated on 
2-12% gradient SDS-PAGE gels at 100 V in electrophoresis buffer (25 mmol/L Tris-HCl (pH 
8.3), 192 mmol/L glycine, 0.1% SDS) and then electrophoretically transferred onto 
nitrocellulose membranes in transfer buffer (25 mmol/L Tris-HCl, 192 mmol/L glycine, 20% 
methanol) overnight at 10 mV. The membranes were incubated in blocking buffer (5% 
nonfat milk in PBS) for 1 hour at room temperature while shaking. The membranes were 
then rinsed with PBS containing 0.1% Tween-20. The membranes were incubated with 
primary antibodies diluted 1∶1000 in 1% milk overnight, washed, and then incubated with 
second antibodies (anti-mouse or anti-rabbit immunoglobulin) diluted 1∶10,000 in 5% milk 
for 1 hour at room temperature while shaking. Immunoreactive proteins were detected 
using enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) (66, 69). 
 
2.2 Materials and Methods for Chapter 4 
 
2.2.1 Cell lines and culture:  All cell lines (MKN45 and SNU-5) were maintained as previously 
described in 2.1.1 methods and grown at 37° C in 5% CO2. 
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2.2.2 Chemicals and antibodies: Crizotinib was purchased from Selleck Chemicals (Houston, 
TX).  Antibodies were obtained from the following sources: MYC from Cell Signaling 
Technology (Beverly, MA); Bim from BD Pharmingen (Piscataway, NJ); anti-mouse/ anti-
rabbit HRP-labeled secondary antibodies from Promega (Madison, WI); and β-actin from 
Sigma-Aldrich (St. Louis, MO). 
2.2.3 Gene expression profiling: SNU-5 and MKN45 cells were plated in 10cm dishes and 
exposed to 100nM crizotinib for 24 hours. Triplicate experiments were performed for each 
cell line and treatment group. Cells were harvested by scraping on ice and washed twice 
with cold PBS. Total RNA from cell pellets was isolated using the mirVana miRNA isolation 
kit (Ambion, Inc) according to manufactures protocol. RNA purity and integrity were 
measured by a NanoDrop ND-1000 spectrophotometer and Agilent Bioanalyzer, 
respectively, and only high-quality RNA was used for the cRNA amplification. The MET-
amplified gastric cancer cell lines were analyzed by direct hybridization on Illumina Human 
HT12v4 chips (Illumina, San Diego, CA). The chips were then scanned on the HiScan or iScan 
systems. Quantile normalization in the Linear Models for Microarray Data (limma) package 
in the R language environment was used to normalize the data. BRB Array Tools version 
4.5.1 (National Cancer Institute) was used to analyze the data. The significantly differentially 
expressed genes (P<0.001 with FDR <0.05, 2-fold cut-off) were then extracted using class 
comparison tools with random variance t-test to yield 1734 differentially expressed probes 
for SNU-5 representing 1405 genes and 1919 differentially expressed probes for MKN45 
representing 1517. Gene expression profiling data was uploaded to Gene Expression 
Omnibus with accession number GSE77320. 
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2.2.4 Pathway Analysis: Functional and pathway analyses were performed using Ingenuity 
Pathway Analysis (IPA) software (Ingenuity® Systems, CA), which contains a database for 
identifying networks and pathways of interest in genomic data. Based on the IPA knowledge 
database, p values and Z-scores can be calculated based on how many targets of each 
transcriptional factor were overlapped (p values) and the extent of concordance of the 
known effects (activation or inhibition) of the targets in the gene lists (Z-score) (70).  
2.2.5 mRNA extraction, reverse transcription and quantitative real-time PCR:  RNA was 
isolated from cells according to the manufacturer’s protocol using the mirVanaTM miRNA 
isolation kit (Ambion/Life Technologies). RNA quantity and quality was then measured by a 
NanoDrop ND-1000 spectrophotometer and samples were diluted to 20ng of RNA. One-
Step RT-PCR kit (Applied Biosystems/Life Technology) was used for real-time (TaqMan-
based) reverse transcription PCR using 96- wells plates. TaqMan primers for PPIA 
(Hs04194521_s1), MYC (Hs00153408_m1), ETV5 (Hs00927557_m1), MXD4 
(Hs01555090_m1) and PIK3IP1 (Hs00364627_m1) were purchased from Applied 
Biosystems. The comparative ΔΔCt method was used to estimate gene expression and the 
data were plotted as relative quantity (CQ) ± min and max as previously described (71). 
2.2.6 Immunoblotting Analysis: Cells were plated and allowed to attach in 6-well plates 
overnight.  The cells were then exposed to 100nM crizotinib and harvested by scraping on 
ice at 24 hours. The western blots were performed as previously described 2.1.6. The 
membranes were incubated with primary BIM and MYC antibodies diluted 1∶1000 in 1% 
milk overnight, washed, and then incubated with second antibodies (anti-mouse or anti-
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rabbit immunoglobulin) diluted 1∶10,000 in 5% milk for 1 hour at room temperature while 
shaking. Immunoreactive proteins were detected using enhanced chemiluminescence 
(Amersham Biosciences, Piscataway, NJ) (69). 
2.3 Materials and Methods for Chapter 5 
 
2.3.1 Cell lines and culture:  All cell lines (MKN45, SNU-5, NUGC-4 and MKN74) were 
maintained as previously described in 2.1.1 methods and grown at 37° C in 5% CO2. 
2.3.2 Chemicals and antibodies: Crizotinib was purchased from Selleck Chemicals (Houston, 
TX). Bortezomib was purchased from ChemieTek (Indianapolis, IN).   Cisplatin was 
purchased from EMD Millipore Corp (Billerica, MA). Propidium iodide, oligomycin A, 
chloroquine and acridine orange were purchased from Sigma-Aldrich (St. Louis, MO). The 
following antibodies were purchased from the indicated sources: Cytochrome C (BD 
Pharmingen); and β-actin (Sigma-Aldrich). 
2.3.3 Acridine orange autophagy detection:  Cells were plated and allowed to attaché 
overnight.  At 30% confluence the cells were exposed to 0, .001, .01,.1 and 1uM crizotinib. 
After 72 hours the cells were washed with cold PBS and dissociated from the plate using 
Accumax to allow for the generation of a single cell suspension. Autophagy levels were 
measured using a lysotropic dye, acridine orange, which accumulates in acidic organelles in 
a pH-dependent manner, becomes protonated and trapped, and emits a bright red 
fluorescence. The red fluorescence was then detected by fluorescence-activated cell sorting 
(Coulter, FL2 channel). Bafilomycin A1 (Sigma Chemical Co.) was dissolved in DMSO and 
added to the cells 30 min before the addition of acridine orange as a positive control.  A 
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negative control containing no AO dye was also generated to accurately gate the 
experiment. 
2.3.4 Cyto-ID autophagy detection: The second method employed to measure autophagy 
within the cells was the use of the CYTO-ID® Autophagy detection kit (Enzo Life Sciences, 
Inc). The cells were plated in 96 well plates at 100μL cells/well (3.0x105 cells/ml), 24 hours 
before the experiment and then exposed to increasing concentrations of crizotinib for 48 
hours. The cells were then washed once with 100 µL of 1X Assay Buffer and then the cells 
were incubated with 100μL of dual color detection solution at 37° for 30 minutes according 
to the manufacturer’s protocol. After 30 minutes the cells were washed twice 1X Assay 
buffer and finally 100μL of 1X Assay Buffer was added to each well. The cells were then 
immediately analyzed by fluorescence microplate reader using the FITC filter (Excitation 
~480 nm, Emission~530) to detect the CYTO-ID® Green detection reagent and the  
DAPI filter set (Excitation ~340, Emission ~480) to detect the nuclear stain (72). 
2.3.5 Immunoblotting Analysis: Cells were plated and allowed to attach in 6-well plates 
overnight.  The cells were then exposed to 100nM crizotinib, 50uM chloroquine or the 
combination of both and harvested at 24 hours. The western blots were performed as 
previously described 2.1.6. The membranes were incubated with primary LC3B antibodies 
diluted 1∶1000 in 1% milk overnight, washed, and then incubated with second antibodies 
(anti-mouse or anti-rabbit immunoglobulin) diluted 1∶10,000 in 5% milk for 1 hour at room 
temperature while shaking. Immunoreactive proteins were detected using enhanced 
chemiluminescence (Amersham Biosciences, Piscataway, NJ) (69). 
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2.3.6 Cell death assay (apoptosis): Cells were plated in 6-well plates and were allowed to 
attach overnight. Cells were then exposed to various concentrations of crizotinib, 
chloroquine, bortezomib or cisplatin for 48 hours and collected via trypsinization. Cell 
pellets were washed once in 2ml of cold PBS and resuspended in 0.5mL of PI-FACS buffer 
which contains: propidium iodide (PI) solution (100μg/mL), triton x-100, sodium citrate and 
PBS for 1-3 hours at 4° with limited exposure to light.  Apoptosis was quantified by 
propidium iodide staining coupled with flow cytometry as previously described 2.1.5 (68).  
2.3.7 Cell viability assay: Cell death was measured using the Vi-CELL XR Cell Viability 
Analyzer (Beckman Coulter) following incubation with the inhibitor for 48 hours. This 
analyzer processes and analyzes cells using the trypan blue dye exclusion method to 
determine the number of viable cells present in a cell suspension. Live cells have 
uncompromised cell membranes that exclude trypan blue dye whereas dead cells do not.  
Viable cells have a clear cytoplasm whereas nonviable cells have a blue cytoplasm. This 
automated process takes the average of 50 unique images to calculate cell viability as well 
as the cell count (73). 
2.3.8 ATP quantification: Cellular ATP levels were measured via the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega). Using the CellTiter-Glo assay, the cell provides 
the ATP needed for the conversion of luciferin so that the luminescence produced is directly 
proportional to the amount of ATP present. Cells were plated in 96 well black plates and 
exposed to increasing doses of crizotinib with or without chloroquine. At 24, 48 and 72 
hours 100ul of CellTiter-Glo reagent was added to each well, and the plate was placed on a 
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shaker for 2 minutes to lyse the cells. The plate was incubated at room temperature for 10 
minutes, and luminescence was then recorded (74).  
2.3.9 Cytochrome c release: Release of cytochrome c from the mitochondria was measured 
by immunoblotting as previously described (75). Cells were incubated with or without 
100nM crizotinib, 50uM chloroquine, or 100nM crizotinib + 50uM chloroquine for 6 hours.  
The cells were then obtained by scraping followed by gentle centrifugation at 1700rpm for 3 
minutes. The pellets were then washed with cold PBS and re-spun for 3 minutes. Next the 
cells were lysed in an ice-cold buffer containing 250 mM Sucrose, 1 mM EDTA, 25 mM Tris, 
pH 6.8, 0.05% IGEPAL and a Complete Mini protease inhibitor tablet (Sigma-Aldrich) until 
the cells outer membrane was compromised as determined by the trypan blue exclusion 
assay. The cells were then centrifuged at 14,000 rpm for 5 min at 4 °C and the supernatant, 
containing the cytosolic fraction, was transferred to new tubes.  The pellet containing the 
mitochondrial fraction was then suspended in lysis buffer, and cytochrome c was measured 
in each fraction by immunoblotting. 
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Chapter 3. SENSITIVITY TO 
CRIZOTINIB IN GASTRIC 
CANCER CELLS IS ASSOCIATED 
WITH MET AMPLIFICATION 
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3.1 Introduction 
 
 As detailed in Chapter 1, genes related to receptor tyrosine kinase (RTK) signaling 
have been identified as therapeutically viable targets in gastric cancer (40). Specifically, MET 
has become a target of interest in gastric cancer cells following positive effects seen in 
preclinical studies by two different groups (Haber and Nakagawa) (42, 43).  Both groups 
showed that MET amplification was associated with sensitivity to MET inhibition. Also, MET 
amplification has been associated with dramatic and prolonged response to MET inhibition 
in gastric cancer patients (76, 77). Although MET inhibitors have clinical activity, not all 
MET-amplified tumors respond, and a deeper understanding of the molecular determinants 
of response is therefore crucial. The results of previous efforts by other groups led to the 
hypothesis that gastric cancer cells with amplified MET are dependent on MET signaling for 
survival and therefore die in response to MET inhibition. 
3.2 Results 
 
3.2.1 Effects of crizotinib on cell proliferation 
 
 As a first step in defining the determinants of MET dependence, we examined 
pharmacologic profiling produced by the Broad Institute for the Cancer Cell Line 
Encyclopedia (CCLE) project.  From the 504 cell lines profiled we extracted all gastric cancer 
cell lines and used this panel of 19 cell lines to examine the sensitivity to the two MET 
inhibitors, PF2341066 (crizotinib) and PHA-665752 [Figure 3.2.a and 3.2.b]. Of these 19 cell 
lines, the only cell line that was sensitive to both MET inhibitors at biologically significant 
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levels was MKN45. Crizotinib is a protein-kinase inhibitor that works by competitive binding 
within the ATP-binding pocket of target kinases [Figure 3.1] (78). Biologically significant 
levels of crizotinib were characterized as IC50 levels less than the peak plasma 
concentration obtained in patients, 57nM (79). Crizotinib selectively targets MET and ALK at 
clinically relevant doses and has a low probability of pharmacologically relevant inhibition of 
other kinases at these doses [Table 3.1] (80). 
 
Figure 3.1 Crizotinib.  (Left) Cocrystal structure of crizotinib bound to c-MET.  Crizotinib 
binds in ATP-competitive manner with an auto-inhibitory kinase conformation of MET (80). 
(Right) 2D crizotinib structure (81).  
*Reprinted with the permission of (80). Copyright 2011, American Chemical Society. 
 
 
 
Table 3.1 Crizotinib kinase selectivity profile.   
*Reprinted with the permission of (80). Copyright 2011, American Chemical Society. 
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A. 
B. 
 
Figure 3.2 Drug sensitivity profiles of gastric human cancer cell lines treated 
with Crizotinib or PHA-665752. (A) Inhibitory concentration 50% (IC50) values of PHA-
665752 in a panel of nineteen gastric cancer cell lines are compared using data generated 
by the CCLE.  (B) Inhibitory concentration 50% (IC50) values of crizotinib in a panel of 
nineteen gastric cancer cell lines are compared using data generated by the CCLE.   
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Additionally, we extracted the crizotinib pharmacologic profiling data for all gastric 
cancer cell lines obtained from the Genomics of Drug Sensitivity in Cancer Project (GDSC) to 
be as comprehensive as possible with our interrogation of publically available 
pharmacologic profiling (82).  The GDSC is collaboration between the Cancer Genome 
Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular 
Therapeutics, Massachusetts General Hospital Cancer Center (USA). Using these data, of the 
five cell lines available (HSC-39, GCIY, SNU-16, SNU-1 and SNU-5) only one (SNU-5) had 
amplified MET and it was also the only cell line that was sensitive to crizotinib [Figure 3.3]. 
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Figure 3.3 Drug sensitivity profiles of gastric human cancer cell lines treated 
with Crizotinib. Inhibitory concentration 50% (IC50) values of crizotinib in a panel of five 
gastric cancer cell lines are compared using data generated by the GDSC.   
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3.2.2 MET gene expression and copy number variation in panel of gastric cancer cell lines 
 
We then correlated the IC50 values for the MET inhibitor crizotinib with MET gene 
expression and MET copy number variation using publicly available data from the Cancer 
Cell Line Encyclopedia (CCLE) project [Figure 3.4.a]. The results revealed that both of the cell 
lines identified as sensitive by the pharmacologic profiling experiments (SNU-5 and MKN45) 
had amplified MET with greater than 10 copies each. The other cell line, Hs746t, which had 
MET amplification and also harbored a MET mutation, was sensitive to only one of the two 
MET inhibitors used by the CCLE (83). The MET mutation identified in the Hs746t cell line 
and its potential consequences will be elaborated on further in the discussion.  
We validated the MET copy number data produced by the CCLE in a panel of 5 cell 
lines, two with MET amplification only (SNU-5 and MKN45), one with wild-type MET (NUGC-
4), one with a MET mutation only (MKN74) and one with MET amplification and a MET 
mutation (Hs746t) using the TaqMan Copy Number Assay [Figure 3.4.b].   
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Figure 3.4 MET gene expression and copy number profile of gastric human 
cancer cell lines. (A) MET RNA expression levels were compared to MET copy numbers 
for a panel of thirteen gastric cancer cell lines using data generated by the CCLE (B) MET 
DNA copy numbers were analyzed using TaqMan copy number assays. Three cell lines 
Hs746t, SNU-5, and MKN45 had high level MET amplification with average copy numbers of 
22, 13 and 20, respectively. Data are means ± SEM from two biological replicates. 
A.  
B
…
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One interesting observation that warranted further investigation is that although the 
NUGC-4 cell line had relatively high levels of MET gene expression, no growth arrest was 
exhibited following MET inhibition.  To further interrogate this finding, we using 
immunoblotting to look at the total and phospho-MET levels in the panel of 5 cell lines 
[Figure 3.5].  The results demonstrated that the amplified cell lines (SNU-5, MKN45, and 
Hs746t) had higher levels of both total and phospho-MET as compared to the MKN74 cells 
that contained mutated MET or the NUGC-4 cells that contained wild-type MET.   
While measuring mRNA is a valid gauge of gene regulation, it cannot be assumed 
that there is a direct correlation between the amount of mRNA and protein expression since 
post-transcriptional processes are key to the final synthesis of the protein (84). Therefore, 
even though the NUGC-4 cells had relatively high mRNA expression they had significantly 
lower levels of total MET and phospho-MET, which appeared to be the primary predictor of 
response to crizotinib, as compared to the amplified cell lines (SNU-5 and MKN45) [Figure 
3.5]. This is reinforced by reports showing a link between phospho-MET levels and 
sensitivity to the MET Inhibitor PHA665752 in lung cancer cells (85).  This supports the idea 
that high levels of phospho-MET may be required for drug sensitivity, an idea which merited 
further inquiry.  
3.2.3 Validation of effects of crizotinib on cell proliferation  
 
Next, we attempted to confirm the results produced by the CCLE and GDSC in an 
independent (but overlapping) panel of 13 gastric cancer cell lines (MKN45, SNU-5, MKN74, 
NUGC-3, NUGC-4, IM95, KATOIII, NCI-N87, SNU-16, HGC-27, AGS, Hs746t, and SNU-1). 
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Figure 3.5 Crizotinib sensitivity correlates with MET phosphorylation in human 
gastric cancer cells.  Three MET amplified (Hs746t, SNU-5, and MKN45) and two non-
amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 
24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then 
analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin 
antibodies. 
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For the results produced by the CCLE, the cells were incubated for 72 to 84 hours 
followed by ATP measurement by luminescence using the Cell Titer Glo assay (Promega) to 
correlate ATP levels to cell survival. For our analysis, we performed 5-day MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays using increasing 
concentrations of crizotinib (ranging from 0, .01-10uM) to measure proliferation inhibition 
and determine IC50 values. At the conclusion of the 5-days conversion of MTT to formazan 
salt was used to measure relative numbers of viable cells in each well.  These data were 
then analyzed and transformed to generate a crizotinib IC50 for each of the cell lines. Then 
we classified the cell lines as either sensitive (<57nM) or resistant (>57nM), based on the 
clinically achievable plasma level of crizotinib in patients. In our panel, the only cell lines 
that were sensitive to clinically achievable concentrations of crizotinib were two of the 
three that contained amplified MET (SNU-5 and MKN45), whereas in our hands the Hs746t 
cells were resistant [Figure 3.6].  Hs764t cells were also resistant to one of the MET 
inhibitors, PHA-665752, tested in the pharmacologic profiling experiments done by the CCLE 
[Figure 3.2.b].  Published data on this cell line presents conflicting results of the total and 
phospho-MET levels as well as sensitivity to MET inhibition which will be elaborated on 
further in the discussion (42, 83). This expands on the idea that although high levels of 
phospho-MET may be required for drug sensitivity, they may not be sufficient for drug 
sensitivity alone.  
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Figure 3.6 Drug sensitivity profile of gastric human cancer cell lines treated 
with Crizotinib.  Thirteen human gastric cancer lines were used to independently 
determine IC50 values of crizotinib in a panel of cancer cell lines. Cells were exposed to 
increasing concentrations of crizotinib for 5 days, and viable cells were assessed using the 
MTT colorimetric assay.  Data are means ± SEM from two biological replicates. 
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3.2.4 Effects of crizotinib on cell death in gastric cancer cells 
 
Based on the previous observation that treatment with crizotinib has cytostatic 
effects on gastric cancer cells containing amplified MET, we speculated that these same 
cells would die via apoptosis following exposure to crizotinib. We then performed a time 
course and dose response in response to crizotinib treatment in a subset of gastric cancer 
cell lines and measured apoptosis by propidium iodide staining coupled with FACS analysis. 
PI/FACS analysis is used  to identify cells with hypodiploid DNA content (68). In this assay 
cells are permeabilized during the PI staining, which results in loss of DNA fragments, 
produced by apoptosis-associated endogenous endonuclease activation, from the cells.  
From this preliminary analysis we decide to move forward with profiling the entire thirteen 
cells lines at the 48 hour time point using the two lowest available concentrations of 
crizotinib that produced significant levels of apoptosis (10nM and 100nM crizotinib) in the 
two MET amplified cell lines.  When the entire panel of cell lines was profiled, only the SNU-
5 and MKN45 cell lines displayed significant increases in crizotinib-induced apoptosis at 
10nM and 100nM crizotinib [Figure 3.7]. This finding that only the MET amplified cell lines 
responded to MET inhibition is consistent with the results of the MTT assays previously 
reported.  
Although the PI-FACS technique has been validated and widely used for the analysis 
of apoptosis since its original publication (68) we sought to confirm these effects using an 
independent assay.  For this, we selected immunoblotting for cleaved poly-(ADP-ribose) 
polymerase (PARP). PARP (116kDA) is involved in DNA damage repair by modifying nuclear 
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proteins and binding DNA breaks.  PARP is cleaved by caspase-3 into an 89kDa fragment 
during apoptosis thus preventing its repair functionality allowing for the progression of 
apoptosis and the resulting hallmark DNA laddering [Figure 3.8.a]. Using the PARP cleavage 
assay, we confirmed that only the cell line with amplified MET (MKN45) responded to 
crizotinib by undergoing apoptosis.  To investigate further the effects of crizotinib on two 
MET amplified cell lines (SNU-5 and MKN45) we examined the modulation of two well-
characterized proteins involved in apoptosis, BIM and XIAP. As mentioned in the 
introduction, BIM upregulation may contribute to the pro-apoptotic effects of crizotinib in 
MET-amplified gastric cancer cells (43). The BH3-only protein BIM is a Bcl-2 family member 
that is essential for the initiation of apoptosis following growth-factor withdrawal (86, 87). 
X-linked Inhibitor of apoptosis (XIAP) is a member of the family of proteins that antagonizes 
apoptosis through binding to inhibits caspase 3, 7 and 9 and deregulation of XIAP has been 
associated with cancer development (88). Based on the PI-FACS and PARP cleavage results 
[Figure 3.7 and 3.8.a] we would anticipate that level of anti-apoptotic protein XIAP (89) 
would decrease, and the level of pro-apoptotic protein BIM (90) would increase following 
exposure to crizotinib in the two MET amplified cell lines. Consistent with our expectations, 
we observed statistically significant changes in protein expression levels between the 
control and crizotinib-treated samples for XIAP and BIM in each cell line (SNU-5 and 
MKN45) [Figure 3.8.b]. Overall, the results demonstrate that MET amplification promotes 
crizotinib induced apoptosis. 
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Figure 3.7 Effects on apoptosis of the MET inhibitor crizotinib on human 
gastric cancer cells.  Thirteen human gastric cancer lines were incubated with or without 
(A) 10nM crizotinib or (B) 100nM crizotinib for 48 hours, and DNA fragmentation 
characteristic of apoptosis was measured by propidium iodide (PI) staining and FACS 
analyses. Values represent normalized results subtracting untreated controls, which were 
all less than 15%. Student t-test, *p≤0.005 crizotinib versus untreated control. 
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Figure 3.8 Effects on apoptosis related proteins of the MET inhibitor crizotinib 
on human gastric cancer cells.  (A) One MET amplified and one non-amplified cell line 
were incubated with or without 100nM crizotinib or 1uM bortezomib for 48 hours. The cells 
were then lysed, and total protein was extracted using RIPA lysis buffer. Total lysates were 
then subjected to immunoblotting analysis using anti-phospho-MET, anti-total-MET, and 
anti-cleaved-PARP antibodies. (B) Two MET amplified cell lines (SNU-5 and MKN45) were 
incubated with 100nM crizotinib for 24hrs and the effects on the anti-apoptotic protein 
XIAP and the pro-apoptotic protein BIM were measured via western blotting.  (C) Bar graphs 
represent quantitative densitometry of the XIAP and BIM protein expression. Data are 
means ± SEM from two independent biological replicates. Student t-test, all groups had 
statistically significant changes in expression between the treated and untreated groups. 
*p≤0.05 
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3.3 Discussion 
 
MET amplification is present in 9-30% (24-26) of gastric cancers and is associated 
with the proximal non-diffuse subtype and generally confers poor patient outcomes (10, 25, 
28). MET has been clinically validated as a therapeutic target in gastric cancer based on 
recent clinical experience (31, 77, 91-93).  We demonstrate that MET-amplified gastric 
cancer cells exhibit growth arrest and cell death in response to incubation with the MET 
inhibitor crizotinib whereas MET inhibition had no significant effects in cells without MET 
amplification, irrespective of whether they had high MET expression or contained MET 
mutations. We show a clear correlation between crizotinib sensitivity and MET amplification 
and identified apoptosis as the mechanism by which the cells are responding to MET 
inhibition. Our results are consistent with previous preclinical observations (42, 43) and 
expand upon these findings by delving deeper into the molecular determinates of response 
to MET inhibition in MET-amplified gastric cancer cells.  We confirmed that in the MET-
amplified cells, expression of BIM (a pro-apoptotic member of the Bcl-2 family) increased 
and X-linked inhibitor of apoptosis protein (XIAP) (anti-apoptotic member survivin) 
decreases following exposure to crizotinib.  
Nevertheless, it was surprising to us that MET inhibitors had no measurable effects 
in the gastric cancer cell lines that contained activating MET mutations, Hs746t and MKN74. 
In particular, one cell line contained a MET mutation in combination with MET amplification 
and was resistant to crizotinib (Hs746t).  One plausible explanation for this observation is 
that Hs746t has a very slow growth rate with a long doubling rate which could account for 
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the lack of apoptosis and growth arrest observed because it would take much longer for 
these processes to occur.  The Hs746t cell line is a mix of epithelial cells and fibroblasts that 
exhibits gross alteration in size, shape, and staining of cells with curious nuclear and 
nucleolar shapes (94). The published literature about this cell line contains conflicting 
results as to its sensitivity to MET inhibitors as well as its level of MET protein expression 
(42, 76, 83, 95).  
Hs746t harbors a splice site mutation (Deletion: L982_D1028del) of MET leading to 
juxtamembrane domain deletion (83). RTKs contain several receptor domains including: 1) 
extracellular domain (EC), 2) single transmembrane domain (TM) and 3) Intracellular 
domain (ICD) (96, 97) [Figure 3.9].  Each domain plays an important role for RTKs. 
Specifically the EC domain contains the ligand binding site and the TM domain allows for 
and maintains receptor dimerization which is the mechanism by which RTK signal 
transduction is accomplished (97).  The intracellular domain consists of three regions the 
juxtamembrane domain (JM), kinase domain, and carboxy-terminal region (96). The kinase 
domain is the site of the ATP-binding pocket which is where crizotinib and other small-
molecule inhibitors bind to prevent RTK activation. Because  Hs746t harbors a JM mutation 
this site is not affected and inhibitor binding is not inhibited (98).The juxtamembrane 
domain works synergistically with the TM and amino acids on the JM serve as binding and 
phosphorylation site for various signaling molecules (99).  JM regulate kinase activity by 
serving as an auto-inhibitory segment, and as a result mutations, deletions and insertions in 
the JM lead to cancer development (100). Specifically, JM mutations found on MET have 
been implicated in inhibiting MET receptor degradation (83, 97). Although, these mutations 
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have been validated as constitutive activators of MET in other cancer types the exact effects 
of these mutations have yet to me elucidated in gastric cancer (101).  Perhaps MET JM 
mutations control some aspect of cancer biology that was not measured in the preclinical 
studies that have been performed to date.  Alternatively, it is possible that activating MET 
mutations act at an early stage in tumor progression and/or become less important in 
established human gastric cancer cell lines. A deeper understanding of these mutations is 
important for the selection of patients for targeted therapeutics and further research into 
this is warranted, albeit outside of the scope of this project. A top priority for ongoing 
investigation for our study focused on identifying strategies that increase MET inhibitor 
sensitivity and overcome the development of the acquired resistance that is likely to 
emerge following prolonged MET inhibition.  
 
Figure 3.9 Receptor tyrosine kinase molecular domains. Schematic of the various 
domains that comprise RTKs: 1) extracellular domain (EC), 2) single transmembrane domain 
(TM) and 3) Intracellular domain (ICD) (96, 97).   
*Reprinted with the permission of the Journal of Bone Oncology. Segaliny, A. I., Tellez-
Gabriel, M., Heymann, M. F., Heymann, D. Receptor tyrosine kinases: Characterization, 
mechanism of action and therapeutic interests for bone cancers. Bone Oncology (2015) (96) 
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Chapter 4.EFFECTS OF 
CRIZOTINIB ON GLOBAL GENE 
EXPRESSION IN GASTRIC 
CANCER CELLS 
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4.1 Introduction 
 
Aberrant tyrosine kinase (TK) signaling is involved in the oncogenic transformation of 
malignant cells, thereby promoting tumor development and progression (102).  This 
abnormal signaling results in “oncogenic addiction” within the cells resulting in the ability to 
impair cell growth and survival by the inactivation of a single oncogene (103).   As a result of 
this “oncogenic addiction,” therapeutics targeting tyrosine kinases and their related 
molecular partners have been developed and extensively tested both pre-clinically and 
clinically (16).  Numerous TK inhibitors have had great clinical success initially, but overall TK 
inhibitors have proven to have limited long-term clinical efficacy due to the emergence of 
adaptive resistance mechanisms (102). These resistance mechanisms are primarily achieved 
through the emergence of additional mutations, modifications to gene copy number and 
protein expression, and rewiring of the molecular pathway [Figure 4.1] (104, 105). One 
famous example of this phenomenon of oncogenic addiction coupled with de novo 
resistance is the use of trastuzumab in the treatment of HER2 positive breast cancer (106). 
Upon its release Trastuzumab was hailed as the “magic bullet” of cancer therapeutics and is 
a very effective anti-cancer agent.  Unfortunately, trastuzumab also proves to be a 
cautionary tale as many patients ultimately go on to have progressive disease following 
their initial response due to the development of acquired resistance (106).  
Therefore gaining a deeper understanding of the molecular determinants of 
response by delving deeper into the gene expression changes is critical to being able to 
predict synergistic and resistance mechanisms. Here we compared the effects of MET 
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inhibition on gene expression in MET two amplified gastric cancer cell lines. We 
hypothesized that overlapping changes in gene expression between the two distinct cell 
lines would identify candidate molecular pathways and biologic mechanisms associated 
with resistance to small-molecule MET inhibitors. 
 
 
Figure 4.1 Acquired resistance mechanisms to TK inhibitors.  Multiple mechanisms 
of acquired resistance can occur in response to exposure of TK inhibitors within cancer cells. 
This figure highlights the progression of acquired resistance in the PI3K signaling pathway, 
but the mechanism applies to other growth-factor receptors. (A) Oncogenic addiction to 
RTK signaling in cancer cells. (B) TK inhibition induces apoptosis in TK addicted cells. (C) 
Acquired resistance mechanisms to TK inhibitors. 
 
*Reprinted with the permission of Nature Publishing Group. Targeting PI3K signalling in 
cancer: opportunities, challenges and limitations. Jeffrey A. Engelman, Nature Reviews 
Cancer 9, 550-562 (August 2009) (107). 
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4.2 Results 
 
4.2.1 Effects on gene expression of the MET inhibitor crizotinib on MET amplified human 
gastric cancer cells. 
 
We sought to define better MET-dependent signaling and mechanisms mediating 
resistance to MET inhibitors in gastric cancers with amplified MET.  To accomplish this, we 
examined changes in gene expression by performing whole-genome mRNA expression 
profiling.  We incubated the inhibitor-sensitive cell lines (MKN45 and SNU-5) with or 
without crizotinib for 24 hours and harvested cell pellets and extracted high-quality RNA to 
use for microarray analysis.  We were then able to look modulation of 47,000 probes using 
the HumanHT-12 v4 Expression BeadChip [Figure 4.2 and 4.3]. In both cell lines, >1400 
genes were differentially expressed under the two conditions [Figure 4.2]. We observed 
substantial overlap between the two cell lines with regard to the genes that were 
differentially expressed following incubation with crizotinib – 406 downregulated and 246 
upregulated genes were shared [Figure 4.2].  We extracted the top 25 upregulated and 
downregulated transcripts in each cell line and observed that this subset was enriched for 
numerous genes related to cell death and cell growth/proliferation [Figure 4.3].  Further 
analyses resulted in the identification of eleven overlapping genes between the two cell 
lines in this subset. Of these, ten genes have been implicated as being directly linked to cell 
death and cell growth/proliferation.  Specifically, we observed downregulation of MYC, 
ETV5, TRIP13, DUSP6, CDC45L, and CALB2 and upregulation of PI3KIP1, SEPP1, ABCA1, and 
HIST1H2AC.  The involvement in tumorigenesis and the modulation of cellular mechanisms 
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pertaining to apoptosis and cell growth proliferation for all of the ten overlapping 
transcripts will be further elaborated on in the discussion section. 
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Figure 4.2 MET inhibition results in significant ch anges in gene expression in 
MET-amplified gastric cancer cell lines.  Graph representing the total number of 
genes that had a P<0.001 with FDR <0.05 and 2-fold cut-off in the two MET amplified cell 
lines following incubation with crizotinib for 24 hours (left). The total number of genes up-
regulated (middle) and down-regulated (right) following incubation with crizotinib for 24 
hours, with the number of common genes between the two cell lines shaded in black. 
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Figure 4.3 Effects on gene expression of the MET inh ibitor crizotinib on MET 
amplified human gastric cancer cells.  Heat map of the top 50 differentially expressed 
genes for each cell line following incubation with crizotinib for 24 hours.  Red, higher 
relative expression; green, lower relative expression. 
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We then performed numerous control experiments to verify the biologic relevance 
of the gene expression profiling experiments.  Using these experiments we wanted to 
confirm that top differentially expressed genes related to cell death and cell 
growth/proliferation identified by gene expression profiling were also differentially 
expressed when they were measured by RT-PCR or immunoblotting in the same cell lines 
[Figure 4.4]. We generated RNA from SNU-5 and MKN45 cells exposed to crizotinib for 24 
hours and measured the relative expression of MYC, ETV5, MXD4, and PIK3IP1 by 
quantitative one-step RT-PCR [Figure 4.4.a and 4.4.b].  Next, we generated protein from 
SNU-5 and MKN45 cells exposed to crizotinib for 24 hours and measured the protein levels 
of MYC by western blotting [Figure 4.4.c]. From these additional analyses, we were able to 
validate that the modulation of the genes and protein measured were consistent with the 
gene expression profiling results. 
4.2.2 Ingenuity Pathway Analysis. 
 
To more clearly define the molecular pathways and biologic functions that were 
altered by drug exposure, we used Ingenuity Pathway Analysis (IPA, Ingenuity Systems; 
http://www.ingenuity.com) to analyze the gene expression profiling data (108). IPA uses a 
global perspective to interpret the context of biological processes, pathways, and networks. 
This is an ideal method since genes cooperate via an intricate network of interactions and 
do not work alone. Using the IPA analysis, we were able to gain a global insight into the 
changes occurring through use of the core analysis feature which generates outputs for 
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canonical pathways, upstream regulators, networks, diseases and biologic functions, toxicity 
functions, and analysis-ready molecules [Figure 4.5].  
 
Figure 4.4 Quantitative RT-PCR was used to evaluate the accuracy of the gene 
expression profiling results.  (A) Selection of the top down-regulated and up-regulated 
genes following treatment with crizotinib in the SNU-5 MET amplified cell line. (B) Selection 
of the top down-regulated and up-regulated genes following treatment with crizotinib in 
the MKN45 MET amplified cell line. (C) Immunoblotting analysis was used to confirm 
significant changes in selected up-regulated and down-regulated genes at the protein level. 
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Figure 4.5 IPA core analysis results. Core analysis results for the top canonical 
pathways and upstream regulators for both SNU-5 and MKN45. 
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We then queried “molecular and cellular functions” in IPA to get a sense of the core 
pathway modulation occurring in response to crizotinib exposure in both MET amplified cell 
lines [Table 4.1]. Molecular and cellular function changes related to cell death, cell cycle, 
cell growth, and proliferation were among the top alterations observed in both MET-
amplified cell lines (SNU-5 and MKN45). 
 
 
Table 4.1 Overall IPA analysis results. Results of IPA analyses of the top molecular and 
cellular functions for MKN45 and SNU-5. 
 
 
 
P-Value # Molecules
4.48E-06 - 9.67E-23 516
9.39E-06 - 2.15E-16 263
2.41E-07 - 1.16E-14 281
8.96E-06 - 1.02E-12 470
4.55E-06 - 1.84E-10 151
P-Value # Molecules
1.77E-06 - 1.34E-24 320
1.24E-06 - 8.08E-22 550
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A deeper investigation of the “Diseases or Functions Annotation” within the cell 
cycle and cell death categories uncovered extensive overlap between the two cell lines in 
regards to the distinct mechanisms that make up the comprehensive categories [Figure 4.6]. 
Within the cell cycle category, the two cell lines shared significant modulation of seven 
distinct functions including interphase, S phase, M phase, cell cycle progression of tumor 
cell lines, entry into interphase, entry into S phase, and interphase of fibroblast cell lines. 
Within the cell death category, the two cell lines shared significant modulation of seven 
distinct functions including cell death of tumor cell lines, necrosis, cell death, apoptosis of 
tumor cell lines, cell survival, cell viability of tumor cell lines, and cell viability. This overlap 
also extended to the cell growth and proliferation category with the overlap of five distinct 
functions including cell proliferation of breast cancer cell lines, cell proliferation of tumor 
cell lines, proliferation of cells, proliferation of connective tissue cells, and proliferation of 
fibroblast cell lines [Figure 4.7]. 
IPA also predicts which transcriptional regulators are involved in the upstream 
cascade that can explain the observed gene expression changes. IPA can then visualize this 
network of regulators and targets to explain how the regulators interact with one another 
and their targets to provide a testable hypothesis for gene regulatory networks. We 
extracted the top inhibited and activated transcriptional regulators for each cell line and 
observed extensive overlap between the two cell lines [Figure 4.8 and 4.9]. The activated 
population was highly enriched with transcription factors involved in cell cycle/proliferation 
arrest and apoptosis activation, whereas the inhibited population was enriched for 
transcription factors involved in cell cycle progression and cellular proliferation.  
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Figure 4.6 Pathway analyses of crizotinib-induced changes in gene expression.  
Significant changes in gene expression were analyzed using Ingenuity Pathway Analysis (IPA) 
using the molecular and cellular functions of the platform. And the cell lines showed 
significant overlap in the identified functions for cell death and cell cycle. 
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Figure 4.7 Additional IPA analysis results . Effects of crizotinib on the IPA “cell growth 
and proliferation” canonical pathway.  
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Figure 4.8 Transcriptional analyses of crizotinib-induced changes in gene 
expression.  Activation z-score and p-value (-log transformed) for significantly activated 
transcriptional regulators from whole genome mRNA expression profiling using IPA. 
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Figure 4.9 Transcriptional analyses of crizotinib-induced changes in gene 
expression.  Activation z-score and p-value (-log transformed) for significantly inhibited 
transcriptional regulators from whole genome mRNA expression profiling using IPA. 
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4.2.3 Gene set enrichment analyses. 
 
We further expanded on our analysis of the gene expression profiling experiments 
by performing gene set enrichment analysis (GSEA) which is a complementary analysis to 
the previous pathway analyses performed using IPA. We began the gene set enrichment 
analysis by using previously identified gene sets available from the molecular signature 
database within GSEA (MSigDB; www.broadinstitute.org/gsea/) (109).  Initially, we queried 
our data using the H: hallmark resource which contains 50 gene sets and is designed to be a 
starting point for exploration within the molecular signature database. The gene sets within 
this collection condense and characterize specific biological processes including P53 
pathway, MYC targets and KRAS signaling just to name a few. We observed that in the SNU-
5 and MKN45 cells 36 and 30 gene sets were significantly enriched, respectively [Table 4.2 
and 4.3].  Of these significantly enriched gene sets, 22 were shared between the two cell 
lines. P53 signaling was positively enriched, and MYC signaling was negatively enriched in 
the treated group following crizotinib exposure [Figure 4.10], which is consistent with the 
IPA results and with the idea that MET inhibition causes decreased cell proliferation/ 
growth and apoptosis induction.  We also discovered that in addition to the previously 
mentioned processes, MTORC1 signaling was downregulated by crizotinib in both cell lines 
[Figure 4.11]. MTORC1’s ability to suppress autophagy is well established, and inhibition of 
MTORC1 induces autophagy (110, 111).  This was of great interest because autophagy is 
well documented as having both tumor suppressive and promoting properties, making it an 
ideal target for our study looking at both synergistic and resistance mechanisms to MET 
inhibition in gastric cancer(50). 
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Table 4.2 GSEA molecular signature database hallmarks gene sets. Gene sets upregulated 
in the crizotinib treatment phenotype with p-values <.05 and NES of <.25 as per the 
suggested cut-offs from GSEA. The gene sets in blue are shared between the two cell lines. 
GENE SET NAME # GENES NES NOM p-val FDR q-val
HALLMARK_BILE_ACID_METABOLISM 112 1.986628 0 0
HALLMARK_PROTEIN_SECRETION 96 1.856694 0 3.14E-04
HALLMARK_HEME_METABOLISM 195 1.759858 0 0.001867
HALLMARK_FATTY_ACID_METABOLISM 156 1.778577 0 0.002002
HALLMARK_ADIPOGENESIS 197 1.725787 0 0.002696
HALLMARK_XENOBIOTIC_METABOLISM 199 1.684998 0 0.003608
HALLMARK_INTERFERON_ALPHA_RESPONSE 96 1.660124 0 0.003756
HALLMARK_KRAS_SIGNALING_DN 198 1.5909 0 0.007554
HALLMARK_P53_PATHWAY 196 1.566838 0 0.008672
HALLMARK_MYOGENESIS 199 1.551734 0 0.009115
HALLMARK_COAGULATION 138 1.52902 0.00339 0.010355
HALLMARK_INTERFERON_GAMMA_RESPONSE 198 1.446082 0.005068 0.02209
HALLMARK_PEROXISOME 102 1.470179 0.01005 0.018397
HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.272327 0.0384 0.099368
HALLMARK_APOPTOSIS 161 1.230343 0.049474 0.132614
GENE SET NAME # GENES NES NOM p-val FDR q-val
HALLMARK_BILE_ACID_METABOLISM 112 1.627883 0.001439 0.02106
HALLMARK_P53_PATHWAY 196 1.653042 0 0.031423
HALLMARK_PANCREAS_BETA_CELLS 40 1.536858 0.023438 0.036237
HALLMARK_KRAS_SIGNALING_DN 198 1.487999 0 0.048577
HALLMARK_APICAL_JUNCTION 199 1.450285 0.002732 0.060757
HALLMARK_MYOGENESIS 199 1.431041 0.003979 0.06274
HALLMARK_HEME_METABOLISM 195 1.38405 0.009383 0.088198
HALLMARK_INTERFERON_ALPHA_RESPONSE 96 1.348254 0.047267 0.108533
SNU-5
MKN45
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Table 4.3 GSEA molecular signature database hallmarks gene sets. Gene sets negatively 
enriched in the crizotinib treatment phenotype with p-values <.05 and NES of <.25 as per 
the suggested cut-offs from GSEA. The gene sets in blue are shared between the two cell 
lines. 
GENE SET NAME SIZE NES NOM p-val FDR q-val
HALLMARK_E2F_TARGETS 189 -3.03282 0 0
HALLMARK_MYC_TARGETS_V1 193 -2.93968 0 0
HALLMARK_G2M_CHECKPOINT 190 -2.8404 0 0
HALLMARK_MYC_TARGETS_V2 57 -2.76023 0 0
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 -2.23322 0 0
HALLMARK_MTORC1_SIGNALING 196 -2.09654 0 0
HALLMARK_MITOTIC_SPINDLE 196 -1.89872 0 0
HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 -1.83644 0 0
HALLMARK_UV_RESPONSE_UP 158 -1.56692 0 0.012095
HALLMARK_DNA_REPAIR 148 -1.47698 0 0.02139
HALLMARK_IL6_JAK_STAT3_SIGNALING 87 -1.5602 0.00232558 0.011774
HALLMARK_GLYCOLYSIS 198 -1.45701 0.00472813 0.023496
HALLMARK_INFLAMMATORY_RESPONSE 200 -1.4008 0.00491401 0.03165
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 -1.41353 0.00497512 0.030683
HALLMARK_SPERMATOGENESIS 130 -1.41771 0.01173709 0.03122
HALLMARK_ALLOGRAFT_REJECTION 200 -1.33962 0.01173709 0.054259
HALLMARK_KRAS_SIGNALING_UP 200 -1.31931 0.02020202 0.061895
HALLMARK_WNT_BETA_CATENIN_SIGNALING 42 -1.55194 0.02340426 0.01143
HALLMARK_HEDGEHOG_SIGNALING 36 -1.48897 0.03393665 0.020886
HALLMARK_IL2_STAT5_SIGNALING 193 -1.29652 0.03496504 0.071825
HALLMARK_HYPOXIA 197 -1.2337 0.04580153 0.114126
GENE SET NAME SIZE NES NOM p-val FDR q-val
HALLMARK_E2F_TARGETS 189 -3.03686 0 0
HALLMARK_MYC_TARGETS_V1 193 -2.91449 0 0
HALLMARK_G2M_CHECKPOINT 190 -2.8715 0 0
HALLMARK_MYC_TARGETS_V2 57 -2.64413 0 0
HALLMARK_MTORC1_SIGNALING 196 -2.34046 0 0
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 -2.22047 0 0
HALLMARK_OXIDATIVE_PHOSPHORYLATION 196 -1.94574 0 2.14E-04
HALLMARK_MITOTIC_SPINDLE 196 -1.82597 0 0.001186
HALLMARK_GLYCOLYSIS 198 -1.81079 0 0.001054
HALLMARK_UV_RESPONSE_UP 158 -1.69578 0 0.002224
HALLMARK_INFLAMMATORY_RESPONSE 200 -1.69074 0 0.00233
HALLMARK_ESTROGEN_RESPONSE_LATE 200 -1.68031 0 0.002715
HALLMARK_IL2_STAT5_SIGNALING 193 -1.53183 0 0.013003
HALLMARK_SPERMATOGENESIS 130 -1.52127 0.00346021 0.013476
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 -1.42877 0.00362319 0.026598
HALLMARK_ESTROGEN_RESPONSE_EARLY 194 -1.35522 0.00364964 0.043127
HALLMARK_DNA_REPAIR 148 -1.38107 0.00716846 0.039951
HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 -1.37308 0.01260504 0.041666
HALLMARK_COMPLEMENT 199 -1.26369 0.01960784 0.079206
HALLMARK_ANDROGEN_RESPONSE 101 -1.36401 0.02380952 0.043446
HALLMARK_KRAS_SIGNALING_UP 200 -1.31319 0.0239726 0.056981
HALLMARK_CHOLESTEROL_HOMEOSTASIS 74 -1.43686 0.02760736 0.027138
SNU-5
MKN45
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Figure 4.10. GSEA analyses of crizotinib-induced changes in gene expression. 
Selection of the top common results within GSEA H: hallmark gene sets from the molecular 
gene sets database are displayed for each of the cell lines. All results have a P<.01 and FDR 
<.05. 
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Figure 4.11. GSEA analyses of crizotinib-induced changes in gene expression.  
MTORC1 is among the top results for both cell lines when using the GSEA curated H: 
hallmark gene sets from the molecular gene sets database with P<.01 and FDR <.05. 
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4.2.4 MET inhibition stimulates an autophagy gene expression signature. 
 
The discovery that MTORC1 was among the top negatively enriched hallmarks gene 
sets in both cell lines prompted us to query the Gene Ontology Consortium (GO): Biologic 
Processes (BP) resource. The GO: BP resource contains 4653 gene sets identified by the 
Gene Ontology Consortium (GO) as enriched in various biologic processes. GO uses 
ontologies to support biologically meaningful annotation of genes and their products as 
determined by the association between specific references, GO terms, and gene products 
(http://geneontology.org/page/guide-go-evidence-codes) (112, 113). 
These analysis identified autophagy as among the top thirty biologic processes 
enriched in both of the two MET-amplified cell lines [Table 4.4]. We looked at all of the 
upregulated gene sets included in the GO: BP resource and identified that of the eight 
autophagy-related gene sets MKN45 and SNU-5 each had at least four that were enriched 
with a p-value <.05 [Table 4.5]. Further investigation of the enrichment plots for the top 
overlapping autophagy gene set between the two cell lines showed great similarities 
[Figure4.12] and, we observed concordance in the modulation of the top autophagy-related 
gene set in both cell lines [Figure 4.13]. This data adds to the GSEA Hallmarks results 
implicating autophagy as a top biologic mechanism that is modulated by MET inhibition in 
MET-amplified gastric cancers and served as a benchmark for the next phase of this project. 
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Table 4.4 GSEA molecular signature database GO:BP gene sets. Gene sets upregulated in 
the crizotinib treatment phenotype with p-values <.05 and NES of <.25 as per the suggested 
cut-offs from GSEA. The gene sets in blue are shared between the two cell lines. 
NAME SIZE NES NOM p-val FDR q-val
GO_LIPID_CATABOLIC_PROCESS 239 2.152469 0 0
GO_GLUTATHIONE_DERIVATIVE_METABOLIC_PROCESS 22 2.064683 0 4.92E-04
GO_FATTY_ACID_METABOLIC_PROCESS 286 2.07081 0 6.56E-04
GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS 22 2.081848 0 9.84E-04
GO_CELLULAR_LIPID_CATABOLIC_PROCESS 147 2.028686 0 0.001779
GO_ETHANOLAMINE_CONTAINING_COMPOUND_METABOLIC_PROCESS 84 2.034813 0 0.001943
GO_PRIMARY_ALCOHOL_METABOLIC_PROCESS 47 2.009606 0 0.002068
GO_ENDOSOME_TO_LYSOSOME_TRANSPORT 40 1.989965 0 0.00325
GO_RETINOL_METABOLIC_PROCESS 29 1.977568 0.0018018 0.003849
GO_UNSATURATED_FATTY_ACID_METABOLIC_PROCESS 105 1.979623 0 0.003851
GO_MONOCARBOXYLIC_ACID_CATABOLIC_PROCESS 92 1.967976 0 0.004441
GO_CARBOXYLIC_ACID_CATABOLIC_PROCESS 199 1.96395 0 0.004742
GO_POST_GOLGI_VESICLE_MEDIATED_TRANSPORT 82 1.969099 0 0.004809
GO_ICOSANOID_METABOLIC_PROCESS 93 1.968001 0 0.004811
GO_RESPONSE_TO_XENOBIOTIC_STIMULUS 105 1.958727 0 0.004813
GO_FATTY_ACID_DERIVATIVE_METABOLIC_PROCESS 93 1.943206 0 0.005458
GO_ORGANIC_ACID_CATABOLIC_PROCESS 199 1.946657 0 0.005657
GO_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS 87 1.943881 0 0.005665
GO_ARACHIDONIC_ACID_METABOLIC_PROCESS 49 1.926438 0 0.007601
GO_VACUOLE_ORGANIZATION 158 1.922182 0 0.008038
GO_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS 63 1.917608 0 0.008205
GO_CHOLESTEROL_EFFLUX 26 1.90631 0 0.010277
GO_ALDITOL_PHOSPHATE_METABOLIC_PROCESS 35 1.902618 0 0.010669
GO_PHOSPHATIDYLETHANOLAMINE_ACYL_CHAIN_REMODELING 22 1.896524 0 0.011586
GO_PHOTORECEPTOR_CELL_MAINTENANCE 33 1.886789 0.0018282 0.013055
GO_POSITIVE_REGULATION_OF_AUTOPHAGY 74 1.88253 0 0.013233
GO_GOLGI_TO_PLASMA_MEMBRANE_TRANSPORT 41 1.87981 0.0018349 0.013344
GO_MEMBRANE_INVAGINATION 28 1.882854 0 0.013594
GO_CILIUM_MORPHOGENESIS 188 1.875818 0 0.013979
NAME SIZE NES NOM p-val FDR q-val
GO_INNATE_IMMUNE_RESPONSE_IN_MUCOSA 21 2.064134 0 0.002695
GO_GLUTATHIONE_DERIVATIVE_BIOSYNTHETIC_PROCESS 22 1.952886 0 0.020348
GO_GLUTATHIONE_DERIVATIVE_METABOLIC_PROCESS 22 1.956883 0 0.026568
GO_PHOTORECEPTOR_CELL_MAINTENANCE 33 1.923241 0 0.030552
GO_GLUTATHIONE_METABOLIC_PROCESS 59 1.905583 0 0.036876
GO_ANTIMICROBIAL_HUMORAL_RESPONSE 45 1.856053 0.0016026 0.05441
GO_RESPONSE_TO_XENOBIOTIC_STIMULUS 105 1.859418 0 0.057542
GO_CILIUM_MOVEMENT 33 1.866313 0 0.05789
GO_CHROMATIN_SILENCING 92 1.845917 0 0.058887
GO_CELLULAR_RESPONSE_TO_ZINC_ION 16 1.87169 0.0034722 0.062079
GO_AXONEME_ASSEMBLY 40 1.837052 0 0.064109
GO_EPOXYGENASE_P450_PATHWAY 18 1.815891 0.0017452 0.065947
GO_EPITHELIAL_CILIUM_MOVEMENT 16 1.818705 0 0.067234
GO_DEFENSE_RESPONSE_TO_GRAM_POSITIVE_BACTERIUM 68 1.820362 0 0.0709
GO_AUTOPHAGOSOME_ORGANIZATION 39 1.796441 0.0048 0.071785
GO_REGULATION_OF_ACROSOME_REACTION 15 1.797629 0 0.074436
GO_VACUOLE_ORGANIZATION 158 1.821857 0 0.074893
GO_VACUOLE_FUSION 22 1.797934 0.0034014 0.078451
GO_CILIUM_MORPHOGENESIS 188 1.79916 0 0.081689
GO_FLAVONOID_METABOLIC_PROCESS 28 1.779221 0.0017036 0.085202
GO_POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER_INVOLVED_IN_CELLULAR_RESPONSE_TO_CHEMICAL_STIMULUS27 1.77964 0 0.088974
GO_ORGAN_OR_TISSUE_SPECIFIC_IMMUNE_RESPONSE 31 1.773162 0 0.089679
GO_PROTEIN_LOCALIZATION_TO_CILIUM 25 1.751528 0.0035524 0.104682
GO_CELLULAR_GLUCURONIDATION 22 1.75883 0 0.105871
GO_GLUCURONATE_METABOLIC_PROCESS 27 1.755923 0 0.105969
GO_CELLULAR_RESPONSE_TO_CADMIUM_ION 15 1.751699 0.0034722 0.108408
GO_DORSAL_VENTRAL_NEURAL_TUBE_PATTERNING 17 1.7451 0 0.110837
GO_POSITIVE_REGULATION_OF_ADHERENS_JUNCTION_ORGANIZATION 21 1.738033 0.0017007 0.113464
GO_URONIC_ACID_METABOLIC_PROCESS 27 1.73937 0.0050251 0.115453
MKN45
SNU-5
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Table 4.5 Autophagy gene sets enriched in the GO:BP gene sets. Autophagy gene sets 
upregulated in the crizotinib treatment phenotype with p-values <.05. The gene sets in blue 
are shared between the two cell lines. 
 
 
NAME SIZE NES NOM p-val
GO_POSITIVE_REGULATION_OF_AUTOPHAGY 74 1.88253 0
GO_AUTOPHAGOSOME_ORGANIZATION 39 1.75685 0.001760563
GO_REGULATION_OF_AUTOPHAGY 240 1.619914 0
GO_AUTOPHAGY 375 1.495902 0
GO_MACROAUTOPHAGY 264 1.432912 0
NAME SIZE NES NOM p-val
GO_AUTOPHAGOSOME_ORGANIZATION 39 1.796441 0.0048
GO_REGULATION_OF_AUTOPHAGY 240 1.576546 0
GO_MACROAUTOPHAGY 264 1.498016 0.002564103
GO_REGULATION_OF_AUTOPHAGOSOME_ASSEMBLY 34 1.496375 0.03322785
SNU-5
MKN45
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Figure 4.12. MET inhibition stimulates an autophagy gene expression 
signature.  Gene set enrichment analysis (GSEA) was used to determine whether a gene 
expression signature associated with autophagy (BP: GO biological process gene set) was 
stimulated by crizotinib in the SNU-5 (P<.01, FDR= .04) and MKN45 (P<.01, FDR= .07) cells. 
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Figure 4.13. MET inhibition stimulates an autophagy gene expression 
signature.  Expression of the top differentially expressed autophagy-associated genes 
included in the GSEA data set (GO autophagosome organization) used in Figure 4.11.  The 
heat maps depict relative expression of autophagy markers in two MET amplified cell lines 
following incubation with crizotinib for 24 hours. Red, higher relative expression; blue, 
lower relative expression. 
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4.3 Discussion 
 
We observed that several of the 50 modulated genes shared between the two cell 
lines were related to cellular proliferation, growth, and apoptosis. Of the eleven genes 
shared between the two cell lines, ten have been directly implicated as involved in the 
previously mentioned cellular processes and their deregulation is associated with 
tumorigenesis.  These included downregulation of MYC, ETV5, TRIP13, DUSP6, CDC45L, and 
CALB2 and upregulation of PI3KIP1, SEPP1, ABCA1, HIST1H2AC following exposure to 
crizotinib. For the most part, this is consistent with the direction of modulation we would 
expect if crizotinib is indeed shutting down proliferation and inducing apoptosis in these 
cells, with the exception being DUSP6 modulation. Dual specificity phosphatase 6 (DUSP6) is 
a member of the family of MAPK phosphatases and modulates BCL-2 family members (Bcl-
2, Bcl-xL, and Bad) expression levels to regulate p53-induced apoptosis (103). DUSP6 also 
inhibits MAPK signal transduction, and previous studies have shown that DUSP6 siRNA 
knockdown results in increased ERK signaling and cellular proliferation (114, 115). Since 
DUSP6 has multiple tumor suppressive mechanisms it was surprising that DUSP6 expression 
decreased following exposure to crizotinib. By delving deeper into this phenomenon, we 
found that other groups have shown that there is significant interaction between crizotinib, 
DUSP6, and ERK which may account for this unexpected finding (116).  
The remaining genes exhibit the expected direction of modulation, and we have 
briefly highlighted the molecular mechanisms involved in cell growth/proliferation and 
apoptosis for each.  The transcription factor ETV5 (Ets-transcript variant 5) is involved in 
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multiple tumorigenic mechanisms in the cell including promoting invasion through 
increased epithelial to mesenchymal transition (EMT) and matrix metalloproteinase 2 
(MMP-2) expression, as well as promoting proliferation through increased downstream 
signaling of the RAS/MAPK pathway (117, 118). MYC is a well-characterized signal 
transducer that promotes cellular growth and proliferation, and MYC deregulation has been 
linked to the tumorigenesis (119, 120).  Thyroid hormone receptor interactor 13 (TRIP13) is 
an ATPase associated with spindle assembly checkpoint inactivation leading to aberrant cell 
transformation due to chromosomal abnormalities (121). Inhibition of TRIP13 is associated 
with decreased cell proliferation, migration, and invasion (122). Cell division cycle protein 
45 (CDC45L) is replication factor that is required for the initiation of DNA replication (123-
125).  CDC45L is found at much higher levels in cancer cells compared to normal human 
cells and overexpression has a positive correlation to proliferation (124). CALB2 (Calretinin) 
is a calcium binding protein that is involved in cell cycle progression (126).  Cells with 
depleted CALB2 have decreased proliferation due to G1 cell cycle arrest (127). PI3KIP1 
(phosphoinositide-3-kinase interacting protein 1) is a well characterized negative regulator 
of PI3K’s that are vital for cell survival and proliferation (128, 129). Upregulation of PI3KIP1 
is associated with apoptosis and tumor suppression (128).  Selenoprotein P (SEPP1) is a 
glycoprotein that transports 60% of selenium in the plasma as well as functioning as a 
potent antioxidant (130). Inhibition of SEPP1 is associated with tumor initiation through 
Wnt signaling and overexpression inhibits proliferation (131). ABCA1 (ATP-binding cassette 
transporter) is a membrane transporter that is upregulated at the mRNA and protein level 
by apoptosis and function to promote the clearance of apoptotic cells by phagocytosis (132, 
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133). Histone H2A type 1-C (HIST1H2AC) is a core histone that helps to make up the 
nucleosome, and its decreased expression is associated with increased proliferation and 
tumorigenicity (134). Overall, the diverse mechanisms that are modulated by just these ten 
defined genes shared between the two cell lines highlights the wide spectrum of molecular 
and biologic mechanisms that are modulated by MET antagonists in MET-amplified cells.  
Because of the diverse mechanisms being modulated by MET inhibition a top 
priority for our ongoing investigation was to identify strategies that increase MET inhibitor 
sensitivity and overcome the development of the acquired resistance that is likely to 
emerge following prolonged MET inhibition. By using whole-genome mRNA expression 
profiling, we were able to identify that genes involved in the regulation of autophagy were 
modulated in both MET inhibitor-sensitive cell lines, and GSEA confirmed that genes 
associated with autophagy were highly enriched following MET inhibition.  Furthermore, 
direct measurements of autophagy are needed to characterize the functional effect that 
exposure to crizotinib causes in both MET amplified gastric cancer cell lines (49, 135).  
Autophagy is a complex process that mediates a variety of different physiological functions, 
including degrading dysfunctional cellular components, protection of organelle function, 
promoting cell survival, decreasing metabolic stress, and executing apoptosis (50, 136). As 
we highlighted in the introduction with regard to cell death, the effects of autophagy are 
context-dependent, resulting in cytoprotective or cytotoxic effects depending on the 
specific physiological or pathological context (136-139).  Because of the complexity of the 
role autophagy plays within the cell and the interest in targeting autophagy to improve the 
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effects of cancer therapies, it was important to understand the role of autophagy following 
MET inhibition in the MET-amplified gastric cancer cells (135, 138, 140). 
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AUTOPHAGYS INVOLVEMENT 
IN RESPONSE TO MET 
ANTAGONIST  
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5.1 Introduction 
 
Previous studies have demonstrated that MET inhibitors induce increases in 
autophagy and autophagy-associated gene expression, but the effect autophagy had on cell 
death, and cell survival in this context was not determined (49, 135).   Autophagy has been 
shown to promote cell death, raising the possibility that blocking autophagy may prevent 
the pro-apoptotic effects of MET antagonist (141-143).  Likewise, autophagy inhibitors have 
been known to promote cell death in cancer cells exposed to other pro-apoptotic agents 
(136, 137, 144), raising the possibility that autophagy inhibitors might promote the effects 
of MET antagonists in human gastric cancer cells.  We, therefore, recognized the clinical 
importance of understanding autophagy’s involvement as it relates to cell death and cell 
survival and therefore sought to evaluate the effects that blocking autophagy has on MET 
inhibitor-induced cell death.  
5.2 Results 
 
5.2.1 Induction of autophagy in response to MET inhibition in MET-amplified gastric 
cancer  
 
We used functional assays in an attempt to confirm the gene expression profiling 
results implicating autophagy as among the top upregulated biologic processes in response 
to MET antagonist in MET-amplified gastric cancer cell lines SNU-5 and MKN45. We used 
two of the drug-resistant gastric cancer cell lines (NUGC-4, MKN74) as controls.  We 
exposed the cells to increasing concentrations of crizotinib for 72 hours and then measured 
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autophagy by acridine orange staining coupled with FACS analysis (145-147).  Crizotinib 
caused concentration-dependent increases in autophagy in both MET-amplified cell lines 
but not in the drug-resistant cells [Figure 5.1].  
 
 
 
Figure 5.1 MET inhibition induces autophagy in the crizotinib -sensitive cells.  
(A) Crizotinib induces autophagy in a concentration-dependent fashion.  The gastric cancer 
cell lines were incubated with increasing concentrations of crizotinib (0, 10, 100, 1000nM) 
for 72 hours and autophagy was accessed by acridine orange staining coupled with flow 
cytometry. The SNU-5 and MKN45 cells contain high level MET amplification, whereas the 
NUGC-4 and MKN74 cells do not.   
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Next, we confirmed the autophagy results using two supplementary independent 
assays. First, we measured autophagic flux using the CYTO-ID autophagy assay which utilizes 
a cationic amphiphilic tracer (CAT) dye that rapidly partitions into cells.  This CAT dye works 
in a similar manner as drugs that induce phospholipidosis (from Enzo Life Sciences, Inc). 
Careful selection of titratable functional moieties on the dye prevents its accumulation 
within lysosomes, but enables labeling of vacuoles associated with the autophagy pathway. 
[Figure 5.2, top panel] (72).  We observed significant increases in autophagy in both MET-
amplified cell lines following exposure to crizotinib. 
 Next, we used immunoblotting to detect conversion of LC3B I to LC3II [Figure 5.2, 
bottom panel]. Microtubule-associated protein 1A/1B-light chain 3 (LC3) plays a role in 
autophagy whereas during autophagy the cytosolic form LC3-I is conjugated to 
phosphatidylethanolamine to form LC3-II which is recruited to the autophagosome (59). 
Degradation (lysosomal turnover) of LC3-II is directly proportional to autophagy activation 
within the cell and is routinely used to monitor autophagy through measurement via 
immunoblotting, immunoprecipitation, and immunofluorescence (59). Following exposure 
to crizotinib, we observed an increase in autophagy in both MET amplified cell lines, as 
determined by an increase in LC3-II conversion [Figure 5.2, bottom panel]. Overall, the 
results of these three assays were consistent with each other and expanded on the results 
of the gene expression profiling by confirming that autophagy is activated following MET-
inhibition.  
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Figure 5.2 MET inhibition induces autophagy in the crizotinib -sensitive cells. 
Conformation of the acridine orange autophagy assay using two additional autophagy 
assays.  (Top Panel) Crizotinib causes increased autophagic flux in the drug-sensitive cells.  
SNU-5 and MKN45 cells were incubated with 100nM crizotinib with for 24hrs and 
autophagy was accessed by fluorescence microplate reader with the application of Cyto-ID 
autophagy detection kit. Data are means ± SEM from three independent experiments. 
Student t-test, *p≤0.05. (Bottom Panel) Crizotinib induces LC3-II processing.  SNU-5 and 
MKN45 cells were incubated with 100nM crizotinib with for 24hrs, and LC3 expression was 
analyzed by Western blotting. 
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5.2.2 Effects of autophagy inhibition on apoptosis         
                                                                                                                                                    
 As detailed in the introduction, depending on the particular biological context, 
autophagy can either promote or inhibit cancer cell death (136, 148).  Therefore, we 
designed mechanistic experiments to define the role of autophagy in crizotinib-induced cell 
death.  First, we examined the effects of blocking autophagy with chloroquine, a clinically 
approved anti-malarial drug that inhibits autophagy by raising lysosomal pH (149, 150).  
Chloroquine did not induce statistically significant increases in the levels of apoptosis in any 
of the cell lines on its own or in combination with crizotinib [Figure 5.3]. On the other hand, 
chloroquine caused a statistically significant decrease in crizotinib-induced apoptosis in the 
MET amplified cell lines (MKN45 and SNU-5) [Figure 5.3].  
We then looked at the effects of chloroquine on other forms of cell death (i.e. 
necrosis) and proliferation. We observed that chloroquine alone induces significant 
increases in the numbers of trypan blue-positive (necrotic) cells in all of the cell lines except 
for the MET-amplified cell line MKN45 [Figure 5.4.A]. We also measured total cell numbers 
following exposure to chloroquine with or without crizotinib and did not observe 
statistically significant decreases in cell numbers, indicative of proliferation inhibition, in any 
of the cell lines [Figure 5.4.B].  We expanded on these results by using live cell imaging at 72 
hours and measuring trypan-blue positivity at 96 hours and observed the same trends as 
the 48-hour data even at these extended time points [Figure 5.5]. Therefore, the decreased 
apoptosis in the chloroquine-exposed MKN45 and SNU-5 cells was not caused by a 
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reduction in total cell numbers due to anti-proliferative effects or alternative cell death 
mechanisms.    
 
 
 
Figure 5.3 Autophagy is required for crizotinib -induced apoptosis.   Gastric 
cancer cell lines (SNU-, MKN45, MKN74, and NUGC-4) were incubated with or without 
100nM crizotinib, 50uM chloroquine (CQ) and 100nM crizotinib + 50uM chloroquine for 48 
hours and PI-FACS was used to quantify cells with fragmented DNA due to apoptosis. 
Student t test, *p≤0.0005. 
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Figure 5.4 Autophagy inhibition effects on cell death and proliferation .  Effects 
on total cell death.  Gastric cancer cell lines (SNU-5, MKN45, MKN74, and NUGC-4) were 
incubated with or without 100nM crizotinib, 50uM chloroquine (CQ) or 100nM crizotinib + 
50uM chloroquine for 48 hours and trypan blue exclusion/ ViCELL was used to quantify total 
cell death (top) and absolute cell numbers (bottom). Data are means ± SEM from three 
independent experiments. Student t-test, *p≤0.05. 
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Figure 5.5 Effects of chloroquine at 72 and 96 hours.   Effects on total cell death.  
Gastric cancer cell lines (SNU-5 and MKN45) were incubated with or without 100nM 
crizotinib, 50uM chloroquine (CQ) or 100nM crizotinib + 50uM chloroquine for 72 hours and 
live cell imaging was performed (top panel) and 96 hours trypan blue exclusion was used to 
quantify total cell death (bottom panel). Data are means ± SEM from three independent 
experiments. Student t-test, *p≤0.05. 
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5.2.3 Anti-apoptotic effects of chloroquine are due autophagy inhibition 
 
We sought to confirm that the anti-apoptotic effects of chloroquine were due to 
autophagy inhibition and not due off-target effects of the drug.  We used RNA interference 
to knock down two obligate components of the autophagy pathway (ATG5 and ATG7) and 
measured the effects of molecular interruption of autophagy on apoptosis induced by MET 
knockdown. We confirmed the knockdown efficiencies of the siRNA silencing by RT-PCR 
[Figure 5.6]. Our results revealed that similar to what we observed in Figure 5.3 knockdown 
of ATG5/7 blocked MET knockdown-induced apoptosis in both of the crizotinib-sensitive cell 
lines but had no effect on the non-amplified cell lines were little apoptosis is observed 
[Figure 5.6].   Next, we measured LC3 conversion by immunoblotting and witnessed a 
buildup of the ratio of LC3-II and LC3-I as expected [Figure 5.7] (150). Chloroquine is a 
lysosomotropic agent that prevents endosomal acidification and leads to inhibition of 
lysosome-autophagosome fusion and lysosomal protein degradation (151).  We also sought 
to confirm that the effects of chloroquine weren’t due to differences in MET expression (i.e. 
an endosome-dependent protein turnover mechanism).  To examine whether chloroquine 
affects steady-state MET levels and/or MET turnover, we examined MET stability in cells 
exposed to chloroquine with or without cycloheximide, an inhibitor of translation [Figure 
5.7]. Although MET levels were indistinguishable in cells that were incubated with or 
without chloroquine alone, they were significantly lower in the cells exposed to chloroquine 
plus cycloheximide compared as compared with cycloheximide alone.  Therefore, 
chloroquine does appear to increase MET turnover, although not enough to inhibit MET 
expression in the absence of cycloheximide.  These effects do not account for the inhibitory 
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effects of chloroquine on crizotinib-induced apoptosis.  From the correlation of previously 
described data, we can conclude that autophagy is directly responsible for the anti-
apoptotic effects of chloroquine.  
 
Figure 5.6 Autophagy is required for crizotinib-induced apoptosis.  (A) Effects on 
apoptosis. Gastric cancer cell lines (SNU-5, MKN45, MKN74, and NUGC-4) were transduced 
with a non-targeting (NT) or MET siRNA, ATG5/7siRNA or MET siRNA + ATG5/7 siRNA for 48 
hours and PI-FACS was used to quantify apoptotic cell death. (B) Knockdown efficiencies for 
MET, ATG5, and ATG7 siRNAs in MKN45 and SNU-5 cells transfected with siRNA for 48 
hours. Expression levels were measured by one-step quantitative RT-PCR. Data are means ± 
SEM from three independent experiments. 
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Figure 5.7 Chloroquine directly modulates autophagy.   (Top) Gastric cancer cell 
lines (SNU-N and MKN45) were incubated with 50uM CQ, and LC3 conversion was used to 
quantify autophagy levels. (Bottom) Gastric cancer cell lines (SNU-N and MKN45) were 
incubated with 50uM CQ +/- cyclohexamide and total MET levels were measured via 
western blotting. 
 
 
 
 
92 
 
5.2.4 MET and Autophagy antagonists modulate metabolic pathways in MET-amplified 
gastric cancer cells. 
 
 The anti-apoptotic effects observed following exposure to chloroquine implicates 
autophagy as a key pro-apoptotic mechanism that warrants further investigation. Additional 
interrogation of the gene expression profiling data revealed that gene signatures associated 
with the two main metabolic pathways, oxidative phosphorylation and glycolysis, were 
negatively enriched following MET inhibition in both of the MET amplified cell lines [Figure 
5.8].  Previous studies demonstrated that apoptosis is an ATP-dependent process, such that 
artificially lowering ATP levels can inhibit apoptotic cell death (152-154).   
Because autophagy provides an energy source for cells undergoing growth factor 
withdrawal-induced stress (140, 155), we wondered whether decreased ATP levels might 
account for the effects of autophagy inhibition on apoptosis in the MKN45 and SNU-5 cells.  
To test this hypothesis, we measured ATP levels in cells at baseline and following exposure 
to chloroquine with or without crizotinib at 24, 48 and 72 hours using the CellTiter-Glo 
assay (156, 157). Consistent with the MTT results, crizotinib caused time- and 
concentration-dependent decreases in ATP levels in both drug-sensitive cell lines (SNU-5 
and MKN45) but had much more modest effects in the two drug-resistant lines (NUGC-4 
and MKN75) [Figure 5.9].  Chloroquine exposure caused major decreases in ATP levels in all 
of the cell lines, and crizotinib had minimal further effects, consistent with a role for 
autophagy in baseline energy homeostasis [Figure 5.10].  Importantly, the ATP levels 
reached following chloroquine exposure were very similar in all of the cell lines.  
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Figure 5.8 MET antagonist decrease metabolic pathways. Oxidative 
phosphorylation and glycolysis are among the top results negatively enriched for both cell 
lines when using the GSEA curated H: hallmark gene sets from the molecular gene sets 
database with P<.01 and FDR <.05 for all gene sets except for SNU-5 oxidative 
phosphorylation. 
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Figure 5.9 MET inhibition lowers ATP levels.  A dose response and time course 
experiment for (A) 24hours (B) 48 hours and (C) 72 hours with increasing concentrations of 
crizotinib to measure ATP levels within the cells. 
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Figure 5.10 MET and autophagy antagonist lower ATP levels. A dose response and 
time course experiment for (A) 24hours (B) 48 hours and (C) 72 hours with increasing 
concentrations of crizotinib in combination with 50uM chloroquine to measure ATP levels 
within the cells. 
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Figure 5.11 MET and metabolic antagonist lower ATP levels . A dose response and 
time course experiment for 24hours (top panel) and 48 hours (bottom panel) with 
increasing concentrations of Oligomycin A and 2-DG with or without 100nM crizotinib in 
combination to measure ATP levels within the cells. 
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5.2.4 Metabolic antagonists do not confer resistance to MET inhibitors. 
 
To determine if decreased ATP levels could cause inhibition of crizotinib-induced 
apoptosis, as we observed following autophagy inhibition via chemical and molecular 
mechanisms, we inhibited ATP production by blocking oxidative phosphorylation and 
glycolysis using the chemical inhibitors oligomycin A and 2-deoxy-D-glucose (2-DG), 
respectively (158) [Figure 5.11].  Chemical reduction of ATP levels had no significant effect 
on apoptosis in the MKN45 of SNU-5 cells [Figure 5.12].  Because chloroquine or chemical 
ATP inhibition reduced ATP levels to a similar extent in the both the SNU-5 and MKN45 
cells, the results demonstrate that MET-amplified gastric cancer cells are not dependent on 
autophagy-mediated ATP production for apoptosis.  Therefore, the anti-apoptotic effects of 
autophagy antagonist are due to another mechanism not related to the energetic 
requirements of apoptosis. 
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Figure 5.12 Metabolic antagonists do not confer resistance to MET inhibition. 
Gastric cancer cells were exposed to oligomycin A and 2-DG with or without 100nM 
crizotinib and PI-FACS was used to measure apoptosis at 48hours. 
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5.2.5 Molecular mechanism behind anti-apoptotic effects of autophagy inhibition  
 
 Our ATP depletion results suggest a lack of Involvement of a general apoptosis-
related mechanism, such as ATP-dependent apoptosome formation. Therefore a crizotinib-
specific mechanism of resistance is more plausible, and further interrogation was necessary.   
Cytochrome c release from mitochondria is a central commitment point for apoptotic cell 
death.  We, therefore, wondered whether autophagy inhibition might attenuate apoptosis 
by preventing crizotinib-induced cytochrome c release [Figure 5.13].  To test this 
hypothesis, we incubated the SNU-5 or MKN45 cells with crizotinib with or without 
chloroquine for 6 hours and measured cytosolic cytochrome c levels by immunoblotting as 
described previously (75).  Crizotinib caused statistically significant inhibition of cytochrome 
c release in both cell lines (representative western blots are displayed in Figure 5.13.a, and 
the results of 3 independent experiments are quantified in Figure 5.13.b).  The results 
support our hypothesis that a resistance mechanism specific to crizotinib-induced apoptosis 
is occurring since cytochrome c release is initiated by BH3-only members of the BCL-2 family 
that are activated by specific upstream stimuli.  Therefore, the localization of the defect to 
some point upstream of cytochrome c release is more consistent with the available data. 
5.2.3 Autophagy inhibition does not confer resistance to other therapeutic agents 
 
Finally, we wondered if the requirement for autophagy to allow cells to undergo 
apoptosis was specific for crizotinib, as suggested by the identification of a crizotinib-
specific defect in the apoptotic cascades, or if it might also be observed with other stimuli 
since the mechanism of activation could be similar for other therapeutic agents. 
 
 
99 
 
 
Figure 5.13 Autophagy is required for crizotinib-induced cytochrome c release.  
(A) Measurement of cytochrome c release by immunoblotting.  The MET-amplified, 
crizotinib-sensitive gastric cancer cell lines (SNU-, MKN45) were incubated with or without 
100nM crizotinib, 50uM chloroquine (CQ) and 100nM crizotinib + 50uM chloroquine for 6 
hours and western blot analysis was used to quantify cytochrome c levels in the cytosol and 
mitochondria. (B) Quantitative densitometry of the protein expression of the cytosolic 
fraction versus the mitochondrial fraction of cytochrome c.  Data are means ± SEM from 
three independent biological replicates. Student t test, *p≤0.05 **p≤0.005. 
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To address this question, first we examined the effects of chloroquine on apoptosis 
induced by two alternative therapeutic agents (cisplatin and bortezomib) [Figure 5.14].  
Bortezomib is an anti-cancer drug that works by inhibiting the proteasome from breaking 
down pro-apoptotic proteins thus allowing cell death to occur (159). Bortezomib is 
commonly used as a single-agent therapy and in combination with chemotherapeutic 
agents in advance stage (metastatic and/or unresectable) gastric cancers (160).  Clinically 
achievable concentrations of bortezomib-induced significant increases in apoptosis in three 
of the four cell lines (MKN45, MKN74, and NUGC-4) [Figure 5.14]. Chloroquine caused a 
modest but statistically significant decrease in bortezomib-induced apoptosis only in the 
MKN45 cells at the highest concentration of bortezomib (100nM, p=0.04) [Figure 5.14.A].  
Cisplatin is a chemotherapy agent commonly used in the treatment of advances 
stage gastric cancer (161, 162). The cytotoxic mechanism employed by cisplatin involves 
damaging DNA and inhibiting DNA synthesis along with inducing apoptosis (163).  In our 
panel of gastric cancer cell lines, we observed that cisplatin increased apoptosis in all four of 
the cell lines [Figure 5.14.B]. Again, as we observed in the bortezomib treated cells, 
chloroquine caused modest (and not statistically significant) decreases in cisplatin-induced 
apoptosis only in the MKN45 cells [Figure 5.14.B].  Together, the results of the bortezomib 
and cisplatin apoptosis experiments support the conclusion that autophagy plays a 
particularly important role in regulating crizotinib-induced apoptosis but is not relevant for 
other therapeutic agents. 
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Figure 5.14 Autophagy is not required for apoptosis induced by other agents.  
(A) Effects of chloroquine on bortezomib-induced apoptosis.  Gastric cancer cell lines (SNU-, 
MKN45, MKN74, and NUGC-4) were incubated with 0, 10 or 100nM bortezomib with or 
without 50uM chloroquine (CQ) for 48hrs hours, and PI/FACS was used to quantify 
apoptosis. (B) Effects of chloroquine on cisplatin-induced apoptosis.  Gastric cancer cell lines 
(SNU-, MKN45, MKN74, and NUGC-4) were incubated with 0, 10 or 25uM cisplatin with or 
without 50uM chloroquine (CQ) for 48hrs hours, and PI/FACS was used to quantify 
apoptosis. Data are means ± SEM from three independent experiments. Student t-test, 
*p≤0.05. 
 
 
102 
 
5.3 Discussion 
 
The functional consequences of activation of an autophagy associated gene 
signature, as observed using IPA and GSEA analysis, correlated with dose-dependent 
increases in autophagy in response to MET antagonist in both MET amplified cell lines.  
Autophagy levels were quantified using three independent assays (acridine orange staining, 
LC3 conversion, and CYTO-ID autophagy assay). Since autophagy activation plays many roles 
within the cells, it was important to define its role within our cells and determine the effects 
of modulating autophagy in combination with MET inhibition.  
Our original hypothesis following the discovery that autophagy is activated by MET 
inhibition was that autophagy inhibition would act as a synergistic mechanism to intensify 
MET-induced apoptosis. What we observed was that in both of the drug-sensitive cell lines 
(MKN45 and SNU-5), autophagy inhibition caused statistically significant decreases in MET 
inhibitor-induced apoptosis regardless of the approach utilized (i.e. direct siRNA-mediated 
knockdown or chemical inhibition).  And deeper analysis of the effects of autophagy 
inhibition on alternate cell death mechanisms (i.e. necrosis) and cell proliferation showed 
negligible effects that did not contribute to the anti-apoptotic effects of autophagy 
inhibition.  
Further analysis of the GSEA results identified the decrease in metabolic pathways in 
both drug-sensitive cell lines. Since autophagy is known to be an alternative mechanism for 
cancer cells to generate cellular energy and apoptosis is an energy dependent form of 
programmed cell death we investigated whether the pro-apoptotic effects of autophagy 
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could be due to the generation of ATP.  We use “chemical hypoxia” experiments to deplete 
ATP from the cells and measure crizotinib-induced apoptosis.  We saw no effect on 
apoptosis following ATP depletion leading us to the conclusion that the defect in apoptosis 
is a crizotinib-specific mechanism and not a more generalized defect in the apoptotic 
cascade (i.e. apoptosome formation, deregulation of the balance of pro- and anti-apoptotic 
proteins, and disruption of P53 signaling). Because in apoptosis mitochondria are the 
central control point with cytochrome c release from the mitochondria being considered 
the proximal commitment point we investigated the effects of autophagy inhibition on 
crizotinib induced apoptosis (164, 165).   Preliminary analyses of the molecular mechanisms 
demonstrated that autophagy was required for crizotinib-induced cytochrome c release. We 
then explored the effects of autophagy inhibition on apoptosis induced by other therapeutic 
agents (cisplatin and bortezomib) commonly used in advanced gastric cancers. Neither 
agent had pronounced levels of apoptosis modulation following the addition of 
chloroquine.  The very modest effects of chloroquine on apoptosis induced by either 
bortezomib or cisplatin support the idea that the effects of chloroquine on apoptosis are 
unique to crizotinib. The results argue against the involvement of a general apoptosis-
related mechanism and further indicate that a defect some point upstream of cytochrome c 
release is more consistent with the available data.  Although these results were surprising 
to us, they are not unprecedented.  Past studies also demonstrated that autophagy was 
essential for apoptosis (63, 136, 166), and another group concluded that autophagy was 
required for cytochrome c release (167), but these effects are highly cell type-dependent 
and additional mechanistic studies are needed to elucidate the exact point of defect.  
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Chapter 6. DISCUSSION, 
CONCLUSIONS AND FUTURE 
DIRECTIONS 
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6.1 Conclusions 
 
The components of this thesis describe key new findings that expand upon the 
current body of knowledge with respect to the consequences of autophagy and MET 
inhibition in gastric cancer. In this section, the central conclusions from chapters 3-5 are 
outlined, and future strategies by which to expand these discoveries are discussed. 
 
6.1.1 Chapter 3 Conclusions: Sensitivity to crizotinib in gastric cancer cells is associated with 
met amplification. 
The data from this chapter expanded on the current knowledge in the field by 
confirming that MET amplification is critical mediator of sensitivity for gastric cancer cells in 
response to MET antagonists and correlating this mediator of sensitivity to high-level MET 
phosphorylation. Here we demonstrate that MET-amplified gastric cancer cells exhibited 
growth arrest and cell death in response to incubation with the MET inhibitor crizotinib, 
whereas MET inhibition had no significant effects in cells without MET amplification, 
irrespective of whether they had high MET mRNA expression or contained activating MET 
mutations.  
Our results are consistent with previous preclinical observations (42, 43) and recent 
clinical experience where MET has been validated as a therapeutic target in gastric cancer 
(77, 91). Although, MET inhibitors have had success in the clinic, some potential drawbacks 
exist and additional investigation into these pitfalls is necessary. These potential downsides 
and future directions are outlined and thoroughly discussed in the next section.  
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6.1.2 Chapter 4 Conclusions:  Evaluation of the effects of crizotinib on global gene 
expression in MET amplified gastric cancer cells 
Recent failures in MET targeted clinical trials with novel MET inhibitors 
onartuzumab, tivantinib, and foretinib combined with our previous observations that 
crizotinib has both cytotoxic and cytostatic effects, resulted in the immediate need to 
identify strategies that increase MET inhibitor sensitivity that can overcome the 
development of the acquired resistance that is likely to emerge following prolonged MET 
inhibition (168-170).  This therefore became a top priority for our studies. Using whole-
genome mRNA expression profiling, we observed genes related to cell death and growth 
arrest were significantly modulated following MET inhibition in both MET amplified cell 
lines. These results support the MTT and PI-FACS data presented in Chapter 3 by confirming 
both growth inhibitory and cell death mechanisms are modulated by MET antagonists.  The 
gene expression changes in each of the cell lines extensively overlapped showing that the 
effects of MET inhibition are more generalized and not cell line specific. This is of great 
importance when trying to identify and streamline targeted therapy options for wide-
ranging classes of patients (i.e. patients with MET amplified tumors) as opposed to being 
focused on individual tumors and patients.  
Additionally, we identified that gene modulation associated with autophagy was 
among the top modulated genes, gene sets, and biologic processes when we performed 
both pathway (IPA) and gene set (GSEA) analysis. As previously detailed in chapter 4, GSEA 
analysis yielded multiple results implicating autophagy related genes as significantly 
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enriched in group exposed to crizotinib.  Additionally using IPA, GATA1 was among the top 
six transcriptional regulators activated in both cell lines.  GATA1 is the master regulator of 
hematopoiesis and we observed in the GSEA hallmarks gene sets heme metabolism is one 
of the six significantly enriched gene sets shared between the two cell lines (171).  This is 
interesting because GATA1 has been directly implicated in activating autophagy 
transcription factors encoding for LC3 as well as employing FOXO3 to activate autophagy 
genes (171). This serves as further evidence that autophagy modulation plays a significant 
role in response to MET inhibition in gastric cancer. 
 Because autophagy has been implicated as both a tumor suppressive and tumor 
promoting process and multiple clinically approved autophagy inhibitors are available, 
autophagy was an ideal target for the next phase of our research looking at possible 
synergistic and resistance mechanisms in response to MET inhibition. 
6.1.3 Chapter 5 Conclusions: Involvement of autophagy in response to MET inhibition in 
MET amplified gastric cancer cells 
Here, we first directly measured autophagy levels using three distinct assays and 
identified that crizotinib induced concentration-dependent autophagy increases in both cell 
lines, consistent with previous reports (49, 135).  Autophagy is a complex process that 
mediates a variety of different physiological functions, including degrading dysfunctional 
cellular components, protection of organelle function, promoting cell survival, decreasing 
metabolic stress, and executing apoptosis (50, 136). With regard to cell death, the effects of 
autophagy are context-dependent, resulting in cytoprotective or cytotoxic effects 
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depending on the specific physiological or pathological context (136-138).  Because of this 
complexity and the interest in targeting autophagy to improve the effects of cancer 
therapies, it was important to understand what role autophagy activation played in 
apoptosis induced by MET inhibition in the MET-amplified gastric cancer cells (135, 138, 
140).  We used PI-FACS to measure apoptosis levels with and without autophagy inhibition 
in both of the drug-sensitive cell lines (MKN45 and SNU-5).  This revealed that autophagy 
inhibition caused statistically significant decreases in MET inhibitor-induced apoptosis, 
regardless of the approach utilized (i.e. direct siRNA-mediated knockdown or chemical 
inhibition).  
We then sought to gain a deeper mechanistic understating of why autophagy in our 
cells is a pro-apoptotic process and where the potential defect in the apoptosis process 
occurred in response to autophagy inhibition. Because the gene expression profiling data 
had been such a valuable resource in identifying biologic processes and molecular 
mechanisms modulated by crizotinib, we mined the top down regulated processes for each 
cell line using the hallmarks gene sets and identified that the metabolic processes, oxidative 
phosphorylation and glycolysis, were down regulated following crizotinib exposure.  Since 
apoptosis is an energy dependent process and autophagy is known to provide energy for 
the cell during times of metabolic stress we hypothesized that ATP depletion was the 
deficiency in the apoptotic process. We measured ATP levels following exposure to 
crizotinib +/- chloroquine and observed a decrease with crizotinib alone and further 
decrease with the addition of chloroquine.  We performed “chemical hypoxia” experiments 
by depleting cellular ATP through exposure to oxidative phosphorylation and glycolysis 
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antagonists and measured ATP levels and crizotinib-induced apoptosis.  We saw no effect 
on apoptosis in either drug-sensitive cell line even though ATP levels were decreased levels 
similar to was observed following chloroquine exposure.  Because the mechanism did not 
appear to be a generalized defect in apoptosis (i.e. ATP dependent apoptosome formation) 
we looked at mechanisms that would be more specific to crizotinib-induced apoptosis. Our 
preliminary analyses of the molecular mechanisms involved demonstrated that autophagy 
was required for crizotinib-induced cytochrome c release, considered the proximal 
commitment point for apoptosis in most examples of the response.   
Additional mechanistic studies are required to determine precisely how autophagy 
promotes cytochrome c release in gastric cancer cells exposed to MET inhibitors. Overall, 
our results suggest that autophagy inhibitors will not potentiate MET inhibitor-induced 
apoptosis in gastric cancer cells.  Clinically, our findings underscore the importance of 
understanding tumor biology prior to launching trials of combination therapies with 
autophagy modulators and growth factor receptor inhibitors in patients.   
6.2 Future Directions: 
 
6.2.1 Chapter 3 Future Directions  
Our studies detailing the relationship between MET amplification and MET inhibitor 
sensitivity in gastric cancer provides an important discovery that upon further experimental 
validation could have significant impact on the way MET inhibitors are used clinically.   The 
recent failures of advanced phase MET inhibitor clinical trials has been largely credited with 
a poor understanding of the most effective method for selecting the appropriate patient 
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populations.  Several methods for measuring MET levels in patients are available and each 
has advantages and pitfalls that need to be addressed prior to initiating studies that require 
specific properties for response. Future studies evaluating the most common clinical 
methods for measuring MET amplification and MET phosphorylation and correlating these 
to determinates of sensitivity that are outlined in our study are of the upmost important. 
We speculate that the currently employed methods are not actually providing an accurate 
picture of these, leading to patient populations enriched with patient that have high mRNA 
MET levels.  mRNA expression levels are a misleading surrogate marker for MET 
amplification that we have shown in chapter 3 does not correlate with response.  Additional 
studies have shown that IHC staining for MET has conflicting outcomes on overall patient 
survival when comparing the two advanced IHC grades (+2 and +3); which is troubling 
because IHC grading is highly subjective and could lead to the selection of inappropriate 
treatment plans for patients as well as skewing patient populations selected for targeted 
therapies (25). Methods used for determining MET status commonly include 
immunohistochemistry (IHC), qPCR, RT-PCR, silver in-situ hybridization (SISH) and 
fluorescence in situ hybridization (FISH), and some preliminary evaluation of their abilities 
to predicate positive patient populations has been accessed (25, 172). To more carefully 
explore the correlation of each of these methods future experiments should include 
retrospective analysis of patient tumors treated with MET inhibitors that can then be 
correlated to clinical response, experiments evaluating the effects of adding HGF ligand to 
cells and gauging the effects of MET inhibition by measuring apoptosis to help discriminate 
between the effects of amplification vs. overexpression of MET, as well as the use of 
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patient-derived xenograft (PDX) models.  These PDX models would allow use to test 
multiple different methods (IHC, RT-PCR, and FISH) that monitor MET amplification and MET 
phosphorylation levels of tumors prior to and throughout treatment with MET inhibitors. 
Another question that merits additional investigation is the need to further 
characterize the cytostatic versus cytotoxic effects of MET inhibition. Our experiments have 
shown that both growth arrest and apoptosis occur in response to exposure to crizotinib 
but we have yet to quantify the ratios of each mechanism in order to evaluate the long term 
usefulness of MET inhibitors.  This can be achieved by employing the use of multiple 
different techniques including the use of clonogenic assays to further describe the effects 
on cell proliferation and survival following treatment with a MET inhibitor and in vivo 
experiments to evaluate the long-term effects of MET antagonists in mouse models with 
orthotopically implanted luciferase-tagged human gastric cell lines. 
6.2.2 Chapter 4 Future Directions 
 In chapter 4, the gene expression profiling experiments generated the data we used 
to more thoroughly explore the effects of autophagy inhibition.  The gene expression 
profiling data also provides leads for additional molecular mechanisms and biologic 
processes that could help identify additional synergistic and resistance mechanisms in 
response to MET inhibition.  One interesting target is KRAS signaling, because it was 
identified in both the upregulated and downregulated hallmarks gene sets for both inhibitor 
sensitive cell lines [Tables 4.2 and 4.2].  KRAS mutations have been identified as a resistance 
mechanism to MET antagonists in MET-driven tumors and further investigation into KRAS 
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modulation could provide valuable insight in the importance of the interaction between 
MET and KRAS (173). Another target, which I outline thoroughly in the chapter 4 discussion, 
is the decreased expression of DUSP6 which is a member of the MAPK family and its 
expression level is modulated by ERK and KRAS.  KRAS and DUSP6 could serve to be a 
therapeutically viable due to the availability of therapeutic agents targeting the MAPK 
cascade (174). Additionally, work done by the TCGA has increased our understanding of 
molecular subtypes in gastric cancer (27). The TCGAs comprehensive mutation, copy-
number and pathway analysis serves as an additional source of knowledge for future 
experiments profiling targetable therapeutic agents in combination with MET antagonists 
(27) [Figure 6.1]. 
6.2.3 Chapter 5 Future Directions 
 Chapter 5 focused on confirming the functional effects of autophagy activation in 
response to MET inhibition.  We discovered a novel resistance mechanism, where 
autophagy is required for cells to undergo apoptosis and then narrowed the point of the 
apoptotic defect to the point of cytochrome c release. Additional mechanistic studies are 
required to determine the exact point of defect in the apoptotic cascade.  Since we 
discovered that it is most likely a defect in apoptosis that is MET-inhibitor specific and not a 
generalized apoptotic mechanism such as apoptosome formation we can achieved this aim 
in several ways.  First we can use western blotting to measure the effects of apoptosis 
related proteins that occur upstream of cytochrome c release.  This will reveal the point at 
which apoptosis fails to occur.  Then we can confirm these results by using knock-down and 
overexpression technology to inhibit or promote proteins related to this defect and 
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measure the functional consequences. Additionally, we would want to see if the effects on 
apoptosis occur in vivo.  Although in vitro cell line analysis is a good preliminary tool, 
ultimately in vivo studies are more clinically relevant. 
 
Figure 6.1 TCGA comprehensive gastric cancer molecular characterizations . “(A) 
Mutations, copy-number changes and translocations for select genes are shown across 
samples organized by molecular subtypes. (B) Alterations in RTK/RAS and RTK/PI3K signaling 
pathways across molecular subtypes. Red denotes predicted activation; blue denotes 
predicted inactivation. (C) The heatmap shows NCI-PID pathways that are significantly 
elevated (red) or decreased (blue) in each of the four subtypes as compared with non-
malignant gastric mucosa.”(27) 
*Reprinted with the permission of Nature Publishing Group. Comprehensive molecular 
characterization of gastric adenocarcinoma.  (2014) The Cancer Genome Atlas Research 
Network (27). 
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6.3 Final Discussion: 
In conclusion, I believe this thesis provides knowledgeable insight into the molecular 
mechanisms related to sensitivity and resistance to MET antagonists in gastric cancer.  The 
advancements and setbacks within the field have only proven to make MET a more 
attractive target for research and the need for better biomarkers, patient selection, and 
MET targeted therapeutics is of the utmost importance. 
While working on this project for the past several years one thing has become 
abundantly clear to me, the future successes of life science research will depend on a 
seamless integration of diverse disciplines. For years biologic researchers have been 
reluctant to collaborate with each other, even within their own institutions. It is my belief 
that collaboration inside our field and from many other fields of study is paramount to the 
future successes of life science advancements.  Fortunately, we have seen advances in the 
way researchers collaborate through the design of large-scale multicenter collaboration 
networks.  The Cancer Prevention and Control Research Network is one such network that 
has propelled the field of cancer prevention through its network of eleven distinct research 
institutions.  Together these institutions have produced 249 multisite collaborative peer-
reviewed scientific publications and contributed to the increase in cancer screening and 
decrease of cancer risk and cancer-related deaths (175). Other networks, such as The 
Cancer Genome Atlas (TCGA) Research Network have also been successful in driving the 
accelerated advancement of breakthroughs in understanding the molecular basis of cancer 
development in 33 cancer types. Through the collaboration of twenty institutions in the 
United States and Canada the TCGA has made breakthroughs in defining cancer sub-types 
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and the genomic foundations of cancer and then translating these results into valid 
therapeutic targets (176).  Despite these advancements in large scale collaborative 
networks focused on cancer management, treatment, and prevention these intra-field 
collaborations are not enough to propel research into the next generation.  We have to 
start utilizing the knowledge and fresh insights that other diverse disciplines can contribute. 
It is my belief that this multi-field collaboration will ultimately lead to break-through 
innovations we would not have otherwise achieved. 
The time I have spent at this world-class cancer institution has given me the tools 
and understanding of how to conduct high quality research as well as the compassion and 
drive to understand how important every experiment is in the race to find the cure for 
cancer. The creation of the “moon shots” initiative has been a driving force in the 
advancement of cancer research worldwide. The parallels are not lost on me between MD 
Andersons initiative and the original “moon shot” program developed by NASA. Neil 
Armstrong was a pioneer of space exploration during a time that we were in our infancy of 
knowledge and understanding in the field, but he knew that “research is creating new 
knowledge” and because of this passion and understanding of the importance of scientific 
research and exploration he became the first man to ever walk on the moon.  I can only 
hope that the drive and passion I have for cancer research will one day make a contribution 
towards fighting the greatest biomedical challenge of my generation.  
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